Top

Keila E. Torres, MD, PhD, MBA, FACS

Department of Surgical Oncology, Division of Surgery

About Dr. Keila E. Torres

Dr. Keila Torres is a Professor in Surgical Oncology at MD Anderson Cancer Center in Houston, Texas. As a surgeon, Dr. Torres specializes in providing surgical care to patients with sarcoma. As a scientist, she also leads a laboratory with the primary goal of understanding how high-grade soft tissue sarcomas, such as Malignant Peripheral Nerve Sheath Tumors (MPNSTs), grow and how they can be treated more efficiently. Dr. Torres' clinical expertise is in soft tissue sarcomas and neurofibromatosis type 1. Dr. Torres is the Co-Director of the Sarcoma Alliance for Collaboration Accelerator Program. She also serves as a scientific reviewer for the Department of Defense.

Primary Appointment

Professor (Joint appointment), Department of Genomic Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Co-Chair, Sarcoma Surgical Care Conference Series (Approved for 1.00 AMA PRA Category 1 Credits), Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Founder and Co-Director, SARC Research/Innovation Catalyst Program, Sarcoma Alliance for Research Through Collaboration, Ann Arbor, MI

Member, Discovery/Translational Committee, Sarcoma Alliance for Research Through Collaboration, The University of Texas MD Anderson Cancer Center, Ann Arbor, MI

Co-Deputy Division Head for Research, Department of Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Mentor, Partnership for Careers in Cancer Science and Medicine Program, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Reviewer, Internal Advisory Committee, U54 Partnership for Excellence in Cancer Research between MD Anderson and the University of Puerto Rico System, The University of Texas MD Anderson Cancer Center, Houston, Texas

Mentor, U54 Partnership for Excellence in Cancer Research between MD Anderson and the University of Puerto Rico System, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Chair, The Lotzova Research Award Committee, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Deputy Sarcoma Section Chief for Research, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

GSBS Faculty Member, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, Texas

Education & Training

Degree-Granting Education

2021	Jesse H. Jones School of Business, Rice University, Houston, Texas, US, Entrepreneurship, MBA
2003	Albert Einstein College of Medicine, Bronx, New York, US, Medicine, MD
2000	Albert Einstein College of Medicine, Bronx, New York, US, Molecular Pharmacology, Ph.D
1996	Albert Einstein College of Medicine, Bronx, New York, US, Molecular Pharmacology, MS
1994	University of Puerto Rico, Rio Piedras, PR, Chemistry, BS, Magna Cum Laude

Postgraduate Training

2008-2011	Clinical Fellowship, Surgical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
2003-2008	Clinical Residency, General Surgery Residency, Robert Wood Johnson University, New Brunswick, New Jersey

Licenses & Certifications

2025	CITI Program GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus)
2025	CITI Program Human Subjects Research
2023	Drug Enforcement Administration (DEA) Researcher
2023	Georgia Composite Medical Board
2023	Tennessee Board of Medical Examiners
2023	Washington Medical Commission
2023	Arizona Medical Board
2023	Alabama Board of Medical Examiners
2023	Louisiana Medical Board
2023	Oklahoma State Board of Medical Licensure & Supervision
2023	Mississippi Medical State Board
2021	Florida Telehealth
2020	Basic Life Support (BLS)
2010	Drug Enforcement Administration (DEA)
2010	American Board of Surgery, Recertification Date: 1/05/2026
2008	Texas Medical Board (TMB)

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2024

Associate Professor (Joint appointment), Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2024

Assistant Professor, Department of Genomic Medicine (joint appointment), The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2017

Assistant Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

Administrative Appointments/Responsibilities

Chair, GSBS Student Scholarship Committee (SSC) for the academic year, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, Texas, 2022 - 2023

Representative and Scientific Reviewer for the Genomic and Epigenetic Program, GSBS Student Scholarship Committee (SSC) for the academic year, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, Texas, 2020 - 2022

Mentor, The Posse Foundation: Career Coaching, Houston, TX, 2017 - 2020

Chair, Sarcoma Surgical Care Conference Series (Approved for 1.00 AMA PRA Category 1 Credits), Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2023

Member, TCGA Sarcoma Analysis Working Group, Bethesda, MD, 2015 - 2019

Co-Leader, Multidisciplinary Sarcoma Database and Tissue Bank, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2014 - 2019

Administrative Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2009 - 2011

Other Professional Positions

Canines-N-Kids Foundation, Medical and Scientific Advisory Group (MSAG), South Riding, VA, 2018 - Present

Scientific Reviewer, Neurofibromatosis Research Program for the Department of Defense Congressionally Directed Medical Research Programs, Fort Detrick, MD, 2013 - 2017

Scientific Reviewer, Career Development - Translational Team Science - Sarcoma (CTT-S) peer review panel of the 2021 Peer Reviewed Cancer Research Program (PRCRP) for the Department of Defense Congressionally Directed Medical Research Programs, Fort Detrick, MD

Scientific Reviewer, Peer Reviewed Cancer Research Program (PRCRP) for the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), Fort Detrick, MD

Extramural Institutional Committee Activities

Member, GSBS Student Success and Well-Being Committee, UTHealth Graduate School of Biomedical Sciences, 2025 - 2028

Member, Chair Search Committee for the General Oncology Department, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Cancer Neuroscience Program (CNP), The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Advanced Scholars Council, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, K12 Calabresi Scholars Internal Advisory Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025

Advisor and Planner Member, G&E Retreat Organizing Committee, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, 2024 - Present

Member, Discovery/Translational Committee, Sarcoma Alliance for Research Through Collaboration, 2022 - Present

Member, GSBS Executive Committee, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, 2022 - 2023

Member, Abdominal Imaging Department Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Member, Genetics and Epigenetics Steering Committee, GSBS UT, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, 2021 - Present

Member, Diversity & Inclusion Committee, Division of Surgery, The University of Texas MD Anderson Cancer Center, 2020 - 2023

Representative of the Genetic and Epigenetic, Scholarship Committee GSBS program, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, 2020 - 2023

Member, Graduate Education Committee (GEC), The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, 2018 - 2021

Group Leader, Student Well-Being and Mental Health Group, Graduate Education Committee (GEC), The University of Texas MD Anderson Cancer Center, 2018 - 2021

Referee, Faculty Academic Review Committee (FARC), The University of Texas MD Anderson Cancer Center, 2015 - 2018

Faculty Member, Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2017

Content Expert, EPIC Committee, Department of Surgical Oncology Sarcoma Service, The University of Texas MD Anderson Cancer Center, 2014 - 2017

Member, Credentials Committee of the Medical Staff, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center

Editorial Activities

Editor, Gastrointestinal Stromal Tumor (GIST), 2020 - Present

Reviewer and Member, Editorial Board for Annals of Surgical Oncology, Sarcoma Section, 2019 - 2023

Editor, Journal of Sarcoma Research, SM Online Scientific Resources LLC, 2017 - Present

Honors & Awards

2024	Nominee for The Office of the Chief Academic Officer R. Lee Clark Award, The University of Texas MD Anderson Cancer Center
2024	Nominee for the FY25 Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
2024	Included in the top 1% of providers nationally ranked by patients for their delivery of care, CAHPS Clinician & Group Survey
2023	Outstanding service as Chair of the Student Scholarship Committee, GSBS Faculty Recognition Award, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences
2022	MD Anderson President's Faculty Honoree for Research Excellence Award, The University of Texas MD Anderson Cancer Center
2019	Ranked Top 10% in the nation by Clinical and Group Consumer Assessment of Healthcare Providers and Systems, CAHPS Clinician & Group Survey
2016	, American College of Surgeons
2015	Young Physician-Scientist Award, The American Society for Clinical Investigation
2015	Commitment to Sarcoma Care Award, Amschwand Sarcoma Cancer Foundation
2013	SARC Career Development Award, Sarcoma Alliance for Research Through Collaboration
2011	Lotzova Research Award, Surgical Oncology, The University of Texas MD Anderson Cancer Center
2011 - 2012	SARC Career Development, Sarcoma Alliance for Research Through Collaboration
2010	Amschwand Sarcoma Foundation Award, Amschwand Sarcoma Cancer Foundation
2010	The Connie and Jim Walter Fellowship in Sarcoma Research, The University of Texas MD Anderson Cancer Center
2009	Amschwand Sarcoma Foundation Award, Amschwand Sarcoma Cancer Foundation
1999	Cardiovascular Association New York Chapter Award, Albert Einstein College of Medicine
1997	AACR Scholar Cancer Research Award, Albert Einstein College of Medicine
1993	MARC/NCI Summer Research Program, National Cancer Institute
1992 - 1994	Minority Access to Research Career (MARC) Program, University of Puerto Rico
1991 - 1992	Minority Biomedical Research Support Research Initiative for Scientific Enhancement Program (MBRS Program), University of Puerto Rico
	Honoree for the FY25 Research Excellence Award, The University of Texas MD Anderson Cancer Center

Professional Memberships

Surgical Biology Club II (SBCII)

International Healthcare Volunteers

Association of American Medical Colleges (AAMC)

Society of University Surgeons (SUS)

American Medical Association (AMA)

Minority Association for Pre-Health Students Mentorship Program, Albert Einstein College of Medicine

American College of Surgeons (ACS)

Connective Tissue Oncology Society (CTOS)

Society of Surgical Oncology (SSO)

Harris County Medical Society (HCMS)

Texas Medical Association (TMA)

Posse Houston Foundation

South Texas American College of Surgeons

Western Surgical Association (WSA)

Selected Presentations & Talks

Local Presentations

2025. Cutting Through Complexity: The Surgical Scientist’s Journey. Invited. Grand Rounds. Houston, Texas, US.
2021. First Gen Latina STEMprenuers, First-Generation Latinas in STEM Meeting. Invited. San Marcos, TX, US.
2015. Women in Science and Medicine. Invited. We Are Girls Conference, Girls Empowerment Network. Houston, TX, US.
2014. Surgical Management of Soft Tissue Sarcomas. Invited. New Braunfels, TX, US.

National Presentations

2025. Unmet Clinical Needs in the Diagnosis and Management of Malignant Peripheral Nerve Sheath Tumors. Invited. Chicago, IL, US.
2023. Epigenetic deregulations in MPNST. Invited. Bethesda, MD, US.
2016. Soft tissue sarcomas. Invited. New York, NY, US.
2015. Sarcoma, a rare, but lethal cancer. Invited. New York, NY, US.
2013. The use of PARP inhibitors for the treatment of MPNST. Visiting. Surgical Research Conference. New York City, NY, US.

International Presentations

2023. Evaluation of The Masspec Pen Technology for Molecular Identification of Bone and Soft Tissue Sarcomas and Surgical Margin Assessment. Invited. 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting. Dublin, IE.
2022. SARC Accelerator Project, Sarcoma Alliance for Research Collaboration (SARC). Invited. Chicago, US.
2022. What You Need to Know about Genetic Syndromes Associated with Sarcomas: Focus on Type 1 Neurofibromatosis. Invited. Dallas, US.
2018. Epigenetic Changes following the Loss of PRC2 in MPNST: Emerging Therapeutic Opportunities, Sarcoma Alliance for Research Collaboration (SARC), Chawla/Rosenfeld Developmental Therapeutics Symposium: Emerging and Novel Biologically Targeted Approaches for Sarcoma Patients. Invited. Rome, IT.
2014. Myxofibrosarcoma: A Complex Surgical Problem. Invited. Phoenix, US.
2012. Radiation-associated soft tissue sarcomas. Invited. Sarcoma Alliance for Research Collaboration (SARC) Meeting. Prague, CZ.

Less

Grant & Contract Support

Date:	2026 - 2027
Title:	Mapping the spatial transcriptomes and proteomes of angiosarcoma in humans and canines to identify common pathways and vulnerabilities
Funding Source:	Department of Defense Rare Cancers Research Program
Role:	PI
ID:	RA250455, 1% effort

Date:	2026 - 2029
Title:	Investigation of Metastatic Drivers of Canine Splenic Hemangiosarcoma through Analysis of the Transcriptome and Comparison to Human Angiosarcoma
Funding Source:	AKC Canine Health Foundation
Role:	Collaborator
ID:	0% effort

Date:	2026 - 2031
Title:	Research Specialist Support for Improving Outcomes in the Treatment of Sarcomas
Funding Source:	NIH/NCI
Role:	Unit Director
ID:	FP00027441, 0% effort

Date:	2026 - 2031
Title:	Fluorescence-Guided Imaging Platform Enhances Tumor Detection and Visualization in Plexiform Neurofibroma Resection
Funding Source:	NIH/NCI
Role:	Co-I
ID:	Stephen I. Katz Early Stage Investigator Research Project Grant, 5% effort

Date:	2026 - 2031
Title:	Unlocking Common Pathways in Angiosarcoma: Comparative Spatial Analysis of Human and Canine Transcriptomes and Proteomes
Funding Source:	CPRIT High Impact High Risk (HIHR) Award
Role:	PI

Date:	2026 - 2027
Title:	Spatial transcriptomic and proteomic analysis of canine and human peripheral nerve sheath tumors
Funding Source:	Congressionally Directed Medical Research Programs (DoD/CDMRP)
Role:	PI
ID:	RA220278, 1.5% effort

Date:	2025 - 2026
Title:	Engineering tumor spheroids and protein complex measurements for malignant peripheral nerve sheath tumors
Funding Source:	Rice-MDA Cancer Bioengineering Collaborative Seed Grant Program
Role:	Co-PI
ID:	1% effort

Date:	2025 - 2030
Title:	Research Education Core, UPR/MDACC Partnership for Excellence in Cancer Research
Funding Source:	NIH/NCI
Role:	Principal Investigator (Multi PI: Sharon Giordano and Paul Scheet)
ID:	U54CA096300, 5% effort

Date:	2025 - 2028
Title:	Accelerating Research on Rare Breast Malignancies Through Development of an Annotated Tissue Repository
Funding Source:	DoD Rare Cancers, Resource Community Development Award
Role:	Consult
ID:	RA240248, 5%

Date:	2025 - 2026
Title:	Building T cell products in NF1-associated MPNST through antigen discovery and epigenome targeting
Funding Source:	Cancer Neuroscience Program (CNP)
Role:	Co-I
ID:	26NN2, 0% effort

Date:	2025 - 2028
Title:	Building T cell products in NF1-associated MPNST through antigen discovery and epigenome targeting
Funding Source:	USAMRAA CDMRP Neurofibromatosis Synergistic Idea Award
Role:	Principal Investigator, (Multi PI: Kunal Rai and Sachet Ashlok)
ID:	NF240072P1, 10% effort

Date:	2024 - 2029
Title:	Research Education Core, UPR/MDACC Partnership for Excellence in Cancer Research
Funding Source:	NIH/NCI
Role:	Principal Investigator (Sharon Giordano, Corresponding PI)
ID:	CA096300-21, 3% effort, Request for NCE submitted

Date:	2024 - 2027
Title:	Development of biomarkers to detect malignancy in patients with NF1
Funding Source:	Department of Defense Neurofibromatosis Synergistic Idea Award
Role:	PI
ID:	NF230010, 10%

Date:	2024 - 2031
Title:	Evaluation of the Mechanism of Response and no Response for Nirogacestat in Desmoid Tumor- Clinical Study
Funding Source:	SpringWorks Therapeutics
Role:	PI
ID:	CS2023-00061121-SG, 10% effort

Date:	2024 - 2026
Title:	In vivo assessment of BET blockade combined with PARP inhibition to sensitize MPNST to radiation therapy
Funding Source:	Children's Tumor Foundation
Role:	PI
ID:	FP00021607, 1% effort

Date:	2024 - 2027
Title:	Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Funding Source:	Neurofibromatosis Investigator-Initiated Award
Role:	PI
ID:	NF230020, 10% effort

Date:	2024 - 2027
Title:	Building T cell products in NF1-associated MPNST through antigen discovery and epigenome targeting
Funding Source:	Department of Defense Neurofibromatosis Synergistic Idea Award
Role:	PI
ID:	NF230100P2, 10%

Date:	2024 - 2027
Title:	Development of a predictive classifier for sarcomas using real-time mass spectrometry
Funding Source:	Congressionally Directed Medical Research Programs
Role:	PI
ID:	RA230125, 10%

Date:	2024 - 2027
Title:	Dependency of RNA Rixosome Complexes: Exploring RNA Surveillance Mechanisms and Epigenetic Regulation in Malignant Peripheral Nerve Sheath Tumors
Funding Source:	American Cancer Society, Postdoctoral Fellowship Award
Role:	Co-Mentor
ID:	FP00021073

Date:	2024 - 2027
Title:	Targeting RNA Surveillance Machinery in NF1-mutant MPNST
Funding Source:	Neurofibromatosis Research Program IIRP Award (QC)
Role:	Co-PI
ID:	NF230063, 10% effort

Date:	2024 - 2026
Title:	Epigenome Dysregulation in NF1-associated Malignant Peripheral Nerve Sheath Tumors
Funding Source:	Department of Defense Neurofibromatosis Early Investigator Research Award
Role:	Co-Mentor
ID:	NF230109

Date:	2024 - 2029
Title:	Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA285980-02, 12% effort

Date:	2024 - 2026
Title:	Investigation and development of novel targeted therapy against malignant peripheral nerve sheath tumors
Funding Source:	Cancer Prevention & Research Institute of Texas
Role:	Co-I
ID:	RP240238, 5%

Date:	2023 - 2024
Title:	Mass Spectrometry Analysis of Malignant Peripheral Nerve Sheath Tumors
Funding Source:	Texas Neurofibromatosis Foundation
Role:	PI
ID:	1%

Date:	2023 - 2028
Title:	Investigation and development of novel targeted therapy against malignant peripheral nerve sheath tumors
Funding Source:	NIH/NCI
Role:	Co-I
ID:	CA286547-01, 5%

Date:	2023 - 2024
Title:	Comparative oncologic study of soft tissue sarcomas
Funding Source:	Earl C. Sams Foundation
Role:	PI
ID:	2%

Date:	2023 - 2025
Title:	Workflow for Prediction of Response of Soft Tissue Sarcomas to Neoadjuvant Therapy using Advanced MRI
Funding Source:	The Fund for Innovation in Cancer Informatics
Role:	Co-I
ID:	FP00018044, 2%

Date:	2023 - 2028
Title:	Mechanisms and therapeutic targeting of RNA surveillance machinery in tumors with loss of Polycomb Repressive Complex-2
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	GRANT13641681, 10%

Date:	2022 - 2024
Title:	Comparative Genomic and Epigenomic Analysis of Canine and Human Soft Tissue Sarcoma
Funding Source:	NIH/NCI
Role:	PI
ID:	1 R21 CA277331-01, 10%

Date:	2022 - 2029
Title:	Preclinical Evaluation of Genetic and Transcriptomic Drivers of Response and Resistance to Nirogacestat in Desmoid Cell Lines and Preclinical Models
Funding Source:	SpringWorks Therapeutics
Role:	PI
ID:	AWD00006975, 2% effort

Date:	2022 - 2027
Title:	Career Enhancement Program (CEP) and Developmental Research Project (DRP)
Funding Source:	MD Anderson Epigenetics SPORE
Role:	Co-Director
ID:	1 P50 CA261606-01A1, 6%

Date:	2022 - 2024
Title:	Leveraging epigenetic deregulations of MPNST to evaluate therapeutic strategies
Funding Source:	Department of Defense
Role:	PI
ID:	NF210018, 1%

Date:	2021 - 2024
Title:	Comparative-Oncology study of Human and Canine MPNST
Funding Source:	Department of Defense
Role:	PI
ID:	GRANT13249430, 5%

Date:	2021 - 2023
Title:	Cross-species genetic evaluation of human and canine malignant peripheral nerve sheath tumors (MPNSTs)
Funding Source:	Andrew Sabin Family Foundation Fellowship Award
Role:	PI
ID:	1%

Date:	2021 - 2022
Title:	Evaluation of canine PNST as an animal model of Human MPNST
Funding Source:	The Hope Foundation for Cancer Research
Role:	PI
ID:	15%

Date:	2020 - 2022
Title:	Cross-species evaluation of canine and human sarcomas
Funding Source:	Earl C. Sams Foundation
Role:	PI
ID:	FP00014428, 1%

Date:	2020 - 2023
Title:	Role of RNA-exosome in PRC2- and NF1-mutant Malignant Peripheral Nerve Sheath Tumors
Funding Source:	Department of Defense
Role:	Co-PI
ID:	NF190074, 5%

Date:	2020 - 2023
Title:	PRC2-dependent enhancer reprogramming promotes MPNST pathogenesis
Funding Source:	Department of Defense
Role:	PI
ID:	NF190050, 15%

Date:	2020 - 2022
Title:	Comparative Oncology, The Texas State I-CorpsTM program
Funding Source:	National Science Foundation
Role:	Entrepreneur Lead

Date:	2020 - 2023
Title:	Distinct PRC2-dependent chromatin landscapes underlie the pathobiology of MPNST
Funding Source:	Cancer Prevention Research Institute of Texas
Role:	PI
ID:	25%

Date:	2019 - 2021
Title:	A Shelter for Cancer Families Foundation Fellowship at MD Anderson's Sarcoma Research Center
Funding Source:	Amschwand Sarcoma Cancer Foundation
Role:	PI
ID:	AWD00004359, 5%

Date:	2019 - 2021
Title:	Combination Drug Analysis of MPNST
Funding Source:	Texas Neurofibromatosis Foundation
Role:	PI
ID:	FP00009040, 1%

Date:	2019 - 2020
Title:	Evolution of the epigenome during MPNST progression
Funding Source:	Sarcoma Foundation of America
Role:	PI
ID:	5%

Date:	2019 - 2021
Title:	Targeted sequencing methylation and ultradeep sequencing of plasma cell-free DNA for early MPNST detection in patients with neurofibromatosis type I
Funding Source:	NCI
Role:	PI

Date:	2019 - 2021
Title:	Targeting DNA damage signaling and epigenetic deregulation as a combination therapy for malignant peripheral nerve sheath tumors
Funding Source:	Children Tumor Foundation
Role:	PI
ID:	FP00007334, 20%

Date:	2019 - 2022
Title:	Development of targeted sequencing methylation assay for plasma cell free DNA from patients with neurofibromatosis type I and MNPST
Funding Source:	Institutional Research Grant
Role:	PI
ID:	600377-30-121685-28, 10%

Date:	2019 - 2020
Title:	Early detection of MPNST in patients with neurofibromatosis type I using plasma cell-free DNA
Funding Source:	Sabin Fellowship Award
Role:	PI
ID:	20%

Date:	2019 - 2021
Title:	Noninvasive biomarkers for detection of NF1-associated MPNSTs using DNA methylation profiles of circulating tumor DNA
Funding Source:	Department of Defense
Role:	PI
ID:	W81XWH-18-NFRP-IIRA, 20%

Date:	2017 - 2021
Title:	Characterization of EZH2's pro-oncogenic activity as a transcriptional modulator in NF1-MPNST
Funding Source:	Department of Defense
Role:	PI
ID:	NF160026, 20%

Date:	2017 - 2022
Title:	Dual role of EZH2 as transcriptional activator and repressor in malignant peripheral nerve sheath tumors and its therapeutic implications
Funding Source:	NIH/NCI
Role:	PI
ID:	PA-16-160, 30%

Date:	2017 - 2021
Title:	EZH2: Oncogenic transcriptional modulator in peripheral nerve sheath tumors
Funding Source:	Research Scholar Grant, American Cancer Society
Role:	PI
ID:	30%

Date:	2017 - 2019
Title:	Characterization of the Methylome in MPNST
Funding Source:	Texas Neurofibromatosis Foundation
Role:	PI
ID:	FP00009040, 2%

Date:	2016 - 2017
Title:	Evaluation of PARP Inhibition in Malignant Peripheral Nerve Sheath Tumors
Funding Source:	Texas Neurofibromatosis Foundation
Role:	PI

Date:	2014 - 2016
Title:	Sensitivity/Specificity of the First Universal Sarcoma CTC Detection Tool
Funding Source:	NCI
Role:	Co-I
ID:	4%

Date:	2013 - 2015
Title:	PARP inhibitors for the treatment of (NF1-associated) MPNST
Funding Source:	Children's Tumor Foundation
Role:	Mentor

Date:	2013 - 2014
Title:	The role of the AKT/mTOR pathway in radiation induced sarcoma
Funding Source:	Sarcoma Alliance for Research through Collaboration
Role:	PI
ID:	6%

Date:	2012 - 2014
Title:	A Shelter for Cancer Families Foundation Fellowship at MD Anderson's Sarcoma Research Center
Funding Source:	Amschwand Sarcoma Cancer Foundation
Role:	PI

Date:	2012 - 2017
Title:	Axl receptor signaling in MPNST; a potential node for therapy
Funding Source:	789,900
Role:	PI
ID:	5-K08-CA160443-04, 75%

Date:	2012 - 2014
Title:	Poly (ADP) Ribose Polymerase (PARP) Inhibitors for the treatment of (NF1-associated) MPNST
Funding Source:	Texas Neurofibromatosis Foundation
Role:	PI

Date:	2012 - 2014
Title:	Role of tyrosine kinase receptor AXL as anti-MPNST therapeutic target
Funding Source:	Institutional Research Grant
Role:	PI
ID:	10%

Date:	2011 - 2016
Title:	Institutional Start Up
Funding Source:	Institutional Grant
Role:	PI

Date:	2010 - 2010
Title:	AKT/mTOR pathway as a therapeutic target for MPNST
Funding Source:	Amschwand Sarcoma Cancer Foundation
Role:	PI

Selected Publications

Peer-Reviewed Articles

Malik N, Kim S, Scally CP, Keung EZ, Lillemoe H, Torres KE, Hunt KK, Khan S, Roland CL, Lyu HG. The impact of vascular management on postoperative complications in patients undergoing surgery for retroperitoneal leiomyosarcoma. Curr. Oncol 33(2):90, 2026. e-Pub 2026. PMID: 41744854.
Guarnerio J, Xiao JF, Ko E, Smith A, Piras R, Fowler A, Ishaya K, Wang L, Wang B, Paulucci-Holthauzen A, Landers S, Bhalla A, Torres KE, Shamsutdinova D, Wani K, Lazar A, Keung E, Somaiah N, Nassif Haddad E. Targeting LPAR4 overcomes stress adaptation to CDK4/6 inhibition in soft tissue sarcoma. Cancer Research. e-Pub 2025.
Xiao JF, Ko E, Smith A, Piras R, Fowler A, Ishaya K, Wang L, Wang B, Paulucci-Holthauzen A, Landers S, Bhalla A, Torres KE, Shamsutdinova D, Wani K, Lazar A, Keung E, Somiah N, Nassif Haddad E, Guarnerio J. Targeting LPAR4 overcomes stress adaptation to CDK4/6 inhibition in soft tissue sarcoma. Cancer Discovery. e-Pub 2025.
Traweek RS, Zoghbi M, Lazcano R, Cope BM, Bishop AJ, Farooqi A, Mitra D, Yoder AK, Guadagnolo BA, Ingram DR, Wani K, Shamsutdinova D, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Ratan R, Livingston JA, Nakazawa MS, Araujo DM, Patel S, Ravi V, Conley AP, Zarzour MA, Somaiah N, Roland CL, Nassif Haddad EF. Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma. ESMO Open 10(7):105493, 2025. e-Pub 2025. PMID: 40561658.
Valenzuela RF, Duran-Sierra E, Antony M, Amini B, Lo S, Torres KE, Hwang KP, Ma J, Stafford RJ, Ratan R, Madewell JE, Araujo D, Jr MW, Costelloe CM. A follow-up study on the novel use of contrast-enhanced susceptibility-weighted imaging for extremity desmoid fibromatosis response assessment. Sci Rep Nat 15(1):20515, 2025. e-Pub 2025. PMID: 40594237.
Elmorsi R, Camacho LD, Krijgh DD, Lyu H, Roubaud MS, Torres KE, Lewis V, Roland CL, Mericli AF. Extremity soft tissue sarcoma reconstruction nomograms: A clinicoradiomic, machine learning-powered predictor of postoperative outcomes. JCO Clin Cancer Inform(9):e2500007. e-Pub 2025. PMID: 40499089.
Valenzuela RF, Duran-Sierra E, Antony M, Amini B, Lo S, Torres KE, Benjamin RS, Ma J, Hwang KP, Stafford RJ, Araujo D, Bishop AJ, Ratan R, Wang WL, Espinoza J, Valenzuela PV, Wu C, Madewell JE, Jr MW, Costelloe CM. Building a pre-surgical multiparametric-MRI-based morphologic, qualitative, semiquantitative, first and high-order radiomic predictive treatment response model for undifferentiated pleomorphic sarcoma to replace RECIST. Cancer Imaging 25(1):56, 2025. e-Pub 2025. PMID: 40281609.
Wang HC, Torres KE, Xia R, Malogolowkin MH, Hsu SW, Chen CH, Shih TC. Galectin-1 inhibition as a strategy for malignant peripheral nerve sheath tumor treatment. Cells 14(7):515, 2025. e-Pub 2025. PMID: 40214469.
Malik N, Krause K, Keung EZ, Lyu HG, Lillemoe H, Scally C, Torres KE, Hunt K, Austin MT, Roland CL. Optimal surveillance for detecting sarcoma lung metastasis – A systematic review. Surg Oncol Insight 2(1):100124, 2025. e-Pub 2025. PMID: 40191537.
Bishop AJ, Mitra D, Farooqi AS, Swanson DM, Hempel CM, Derrick TW, Pearlnath CG, Wang WL, Ratan T, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher R, Bird JE, Lin P, Moon BS, Lewis VO, Roland CL, Guadagnolo A. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): updated local control, late-toxicities and patient-reported outcomes. Cancer 131(1):e35542, 2025. e-Pub 2024. PMID: 39192597.
Valenzuela RF, Duran-Sierra E, Canjirathinkal MA, Armini B, Hwang KP, Ma J, Torres KE, Stafford JR, Wang WL, Benjamin RS, Bishop AJ, Madewell JE, Murphy WA, Costelloe CM. Novel use and value of contrast-enhanced susceptibility-weighted imaging morphologic and radiomic features in predicting extremity soft tissue undifferentiated pleomorphic sarcoma treatment response. JCO Clin Cancer Inform(9):e2400042, 2025. e-Pub 2025. PMID: 39841956.
Tomczak K, Patel MS, Bhalla AD, Peterson CB, Landers SM, Callahan SC, Zhang D, Wong J, Landry JP, Lazar AJ, Livingston JA, Guadagnolo BA, Lyu HG, Lillemoe H, Roland CL, Keung EZ, Scally CP, Hunt KK, McCutcheon IE, Slopis JM, Gu J, Scheet P, Wang L, Rai K, Torres KE. Plasma DNA methylation-based biomarkers for MPNST detection in patients with neurofibromatosis type 1. Mol Carcinog 64(1):44-56, 2025. e-Pub 2024. PMID: 39600120.
Lyu HG, Witt RG, Rajkot N, Keung EZ, Torres KE, Hunt KK, Somaiah N, Lazar AJ, Roland CL, Scally CP. Patterns of care and outcomes of patients with small gastrointestinal stromal tumors at a high-volume sarcoma center. Ann Surg Oncol 31(13):9258-9264, 2024. e-Pub 2024. PMID: 39230849.
Gingrich A, Wangsiricharoen S, Torres M, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar A, Wang WL, Roland CL, Feig B, Hunt KK, Yu W, Torres KE. Clinical variables influencing outcomes in atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): Single institution study of 95 surgical patients. Ann Surg Oncol 31(12):7950-7956, 2024. e-Pub 2024. PMID: 39150618.
Wang HC, Torres KE, Xia R, Malogolowkin M, Hsu SW, Chen CH, Shih TC. Targeting the galectin-1/ras interaction for treating malignant peripheral nerve sheath tumors. Research Square Reprint(16):rs.3.rs-5263500, 2024. e-Pub 2024. PMID: 39483902.
Valenzuela RF, Duran-Sierra E, Canjirathinkal M, Amini B, Torres KE, Benjamin RS, Ma J, Wang WL, Hwang KP, Stafford RJ, Wu C, Zarzour AM, Bishop AJ, Lo S, Madewell JE, Kumar R, Jr MW, Costelloe CM. Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment response. Sci Rep 14(1):21681, 2024. e-Pub 2024. PMID: 39289469.
Valenzuela RF, Duran-Sierra E, Canjirathinkal M, Amini B, Torres KE, Benjamin RS, Ma J, Wang WL, Hwang KP, Stafford RJ, Wu C, Zarzour AM, Bishop AJ, Lo S, Madewell JE, Kumar R, Murphy Jr WA, Costelloe CM. Radiomics by quantitative diffusion-weighted MRI for predicting response in patients with extremity soft-tissue undifferentiated pleomorphic sarcoma. J Radiol Oncol 8(2):064-071, 2024. e-Pub 2024.
Traweek RS, Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. High community-level social vulnerability is associated with worse recurrence-free survival (RFS) after resection of extremity and truncal soft tissue sarcoma. Ann Surg Oncol 31(6):4138-4147, 2024. e-Pub 2024. PMID: 38396039.
Traweek RS, Lyu H, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. ASO Visual Abstract: High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival Following Resection of Extremity and Truncal Soft-Tissue Sarcoma. Ann Surg Oncol 31(6):4150-4151, 2024. e-Pub 2024. PMID: 38546800.
Valenzuela RF, Duran-Sierra E, Canjirathinkal MA, Amini B, Ma J, Hwang KP, Stafford RJ, Torres KE, Zarzour MA, Livingston JA, Madewell JE, Murphy WA, Costelloe CM. Contrast-enhanced susceptibility weighted imaging (CE-SWI) for the characterization of musculoskeletal oncologic pathology: a pictorial essay on the initial five-year experience at a cancer institution. J Radiol Oncol(8):030-046, 2024. e-Pub 2024.
Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
Witt RG, Voss RK, Chiang YJ, Nguyen S, Scally CP, Lin PP, Torres KE, Moon BS, Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. Practice pattern variability in the management of regional lymph node metastasis in extremity and trunk soft tissue sarcoma (ETSTS): A survey of the Society of Surgical Oncology (SSO) and Musculoskeletal Tumor Society (MSTS) Membership. Ann Surg Oncol 30(6):3668-3676, 2023. e-Pub 2023. PMID: 36723723.
Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Ann Surg Oncol 30(2):926-940, 2023. e-Pub 2023. PMID: 36115928.
Traweek RS, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. Re-excision after unplanned excision of soft tissue sarcoma is associated with high morbidity and limited pathologic identification of residual disease. Ann Surg Oncol 30(1):480-489, 2023. e-Pub 2023. PMID: 36085392.
Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node biopsy and formal lymphadenectomy for soft Tissue sarcoma – A single center experience of 86 consecutive cases. Ann Surg Oncol 29(11):7092-7100, 2022. e-Pub 2022. PMID: 35501583.
Rasmussen SV, Jin JX, Bickford LR, Woods AD, Sahm F, Crawford KA, Nagamori K, Goto H, Torres KE, Sidoni A, Rudzinski ER, Thway K, Jones RL, Ciulli A, Wright H, Lathara M, Srinivasa G, Kannan K, Huang PH, Grünewald TGP, Berlow NE, Keller C. Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. Clin Transl Med 12(7):e961, 2022. e-Pub 2022. PMID: 35839307.
Bhalla AD, Landers SM, Singh AK, Landry JP, Yeagley MG, Myerson GSB, Delgado-Baez CB, Dunnand S, Nguyen T, Ma X, Bolshakov S, Menegaz BA, Lamhamedi-Cherradi SE, Mao X, Song X, Lazar AJ, McCutcheon IE, Slopis JM, Ludwig JA, Lev DC, Rai K, Torres KE. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. Lab Invest 102(6):658-666, 2022. e-Pub 2022. PMID: 35228656.
Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-World use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer 150(12):2012-2024, 2022. e-Pub 2022. PMID: 35128664.
DiPeri TP, Newhook TE, Day RW, Chiang YJ, Dewhurst WL, Arvide EM, Bruno ML, Scally CP, Roland CL, Katz MHG, Vauthey JN, Chang GJ, Badgwell BD, Perrier ND, Grubbs EG, Lee JE, Tzeng CD, PROMOTE Consortium, Torres KE, et al. A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients. Surg Open Sci 25(9):51-57, 2022. e-Pub 2022.
Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. ASO Visual Abstract: Sarculator is a good model to predict survival in resected extremity and trunk sarcomas in US patients. Ann Surg Oncol. e-Pub 2022. PMID: 35254579.
Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. Sarculator is a good model to predict survival in resected extremity and trunk sarcomas in US patients. Ann Surg Oncol. e-Pub 2022. PMID: 35224688.
Selber JC, Kameni L, Torres KE, Mericli A, Chu C, Schaverien M, Largo R, Butler C, Gaber O. Successful double DIEP syngeneic transplantation across monozygotic twins for total back reconstruction. Plast Reconstr Surg 148(5):1125-1133, 2021. e-Pub 2021. PMID: 34705789.
Kochat V, Raman AT, Landers SM, Tang M, Schulz J, Terranova C, Landry JP, Bhalla AD, Beird HC, Wu CC, Jiang Y, Mao X, Lazcano R, Gite S, Ingram DR, Yi M, Zhang J, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Futreal PA, Hwu P, Wang WL, Lazar AJ, Slopis JM, Wilson-Robles H, Wiener DJ, McCutcheon IE, Wustefeld-Janssens B, Rai K, Torres KE. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol 142(3):565-590, 2021. e-Pub 2021. PMID: 34283254.
Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open 4(3):e210945, 2021. e-Pub 2021. PMID: 33734413.
Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CL. Evaluating the impact of surveillance follow-up intervals in patients following resection of primary well-differentiated liposarcoma of the retroperitoneum. Ann Surg Oncol 28(1):570-575, 2021. e-Pub 2021. PMID: 32409969.
Xu Y, Tsai CW, Chang WS, Xiong GY, Huang M, Torres KE, Bau DT, Gu J. Genetically predicted high circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 increase the risks of soft tissue sarcoma. Am J Cancer Res 11(8):3980-3989, 2021. e-Pub 2021. PMID: 34522462.
Keung EZ, Asare EA, Chiang YJ, Prakash LR, Rajkot N, Torres KE, Hunt KK, Feig BW, Cormier JN, Roland CL, Katz MHG, Lee JE, Tzeng CD. Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. Am J Surg 220(1):140-146, 2020. e-Pub 2020. PMID: 31843190.
Batth IS, Meng Q, Wang Q, Torres KE, Burks J, Wang J, Gorlick R, Li S. Rare osteosarcoma cell subpopulation protein array and profiling using imaging mass cytometry and bioinformatics analysis. BMC Cancer 20(1):715, 2020. e-Pub 2020. PMID: 32736533.
Bishop AJ, Landry JP, Roland CL, Ratan R, Feig BW, Moon BS, Zarzour MA, Wang WL, Lazar AJ, Lewis VO, Torres KE, Guadagnolo BA. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer 126(14):3265-3273, 2020. e-Pub 2020. PMID: 32343846.
Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres KE, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a diagnostic tool in distinguishing well-differentiated versus dedifferentiated liposarcoma. Sarcoma, 2020. e-Pub 2020.
Xu Y, Xu J, Chancoco H, Huang M, Torres KE, Gu J. Long leukocyte telomere length is associated with increased risks of soft tissue sarcoma: A mendelian randomization study. Cancers (Basel) 12(3):594, 2020. e-Pub 2020. PMID: 32150919.
Asare EA, Davis CH, Chiang YJ, Sabir S, Rajkot NF, Phillips PR, Roland CL, Torres KE, Hunt KK, Feig BW. Management and outcomes of ruptured, perforated or fistulized tumors of mesenchymal origin. J Surg Oncol 121(3):474-479, 2020. e-Pub 2020. PMID: 31846095.
Landers SM, Bhalla AD, Ma X, Lusby K, Ingram D, Al Sannaa GA, Wang WL, Lazar AJ, Torres KE. AXL inhibition enhances MEK inhibitor sensitivity in malignant peripheral nerve sheath tumors. J Cancer Sci Clin Ther 4(4):511-525, 2020. e-Pub 2020.
Chrisinger JSA, Al-Zaid T, Keung EZ, Leung C, Lin HY, Roland CL, Torres KE, Benjamin RS, Ingram DR, Khan S, Somaiah N, Amini B, Feig BW, Lazar AJ, Wang WL. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol 120(3):382-388, 2019. e-Pub 2019.
Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig BW, Wang WL, Lazar AJ, Moon BS, Roland CL, Guadagnolo BA. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: an effective treatment but with poorer outcomes among young patients. Int J Radiat Oncol Biol Phys 103(5):1167-1174, 2019. e-Pub 2019. PMID: 30552963.
Fisher SB, Chiang YJ, Feig BW, Cormier JN, Hunt KK, Torres KE, Roland CL. An evaluation of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system for retroperitoneal sarcomas using the National Cancer Data Base (NCDB): Does size matter?. Am J Clin Oncol 42(2):160-165, 2019. e-Pub 2019. PMID: 30394881.
Fonseca AL, Roland CL, Cormier JN, Torres KE, Hunt KH, Bishop AJ, Guadagnolo A, Feig BW. Radiation and its impact on local recurrence in extremity and trunk well-differentiated liposarcomas. Am Surg 85(1):52-58, 2019. e-Pub 2019. PMID: 30760345.
Keung EZ, Chiang YJ, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer 124(23):4495-4503, 2018. e-Pub 2018. PMID: 30317543.
Young ED, Ingram D, Metcalf-Doetsch W, Khan D, Al Sannaa GA, Le Loarer F, Lazar AJ, Slopis J, Torres KE, Lev D, Pollock RE, McCutcheon IE. Clinicopathologic variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. J Neurosurg 129(3):805-814, 2018. e-Pub 2018. PMID: 28885122.
Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
Shasby G, Young ED, Ingram D, Metcalf-Doetsch W, Khan D, Al Sannaa G, Le Loarer F, Lazar AJF, Slopis J, Torres KE, Lev D, Pollock RE, McCutcheon IE. Erratum: Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. J Neurosurg 129(3):838, 2018. e-Pub 2018. PMID: 29125411.
Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Salvage surgery for recurrent retroperitoneal well-differentiated liposarcoma: Early reoperation may not provide benefit. Ann Surg Oncol 25(8):2193-2200, 2018. e-Pub 2018.
Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A rertrospective cohort study at a major sarcoma center. J Surg Oncol 117(6):1188-1194, 2018. e-Pub 2018.
Bishop AJ, Zagars GK, Torres KE, Bird JE, Feig BW, Guadagnolo BA. Malignant peripheral nerve sheath tumors: A single institution's experience using combined surgery and radiation therapy. Am J Clin Oncol 41(5):465-470, 2018. e-Pub 2018.
Fisher SB, Chiang YJ, Feig BW, Cormier JN, Hunt KK, Torres KE, Roland CL. Comparative performance of the 7th and 8th editions of the American Joint Committee on Cancer staging systems for soft tissue sarcoma of the trunk and extremities. Ann Surg Oncol 25(5):1126-1132, 2018. e-Pub 2018.
Ikoma N, Roland CL, Cormier JN, Chiang YJ, Torres KE, Hunt KK, You YN, Feig BW. Nongastrointestinal stromal tumor spindle cell sarcomas of the colon or rectum. Am Surg 84(4):570-575, 2018. e-Pub 2018. PMID: 29712608.
Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BW. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol 117(5):879-885. e-Pub 2018.
Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li S. Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncolmmunology 7(5):e1420450. e-Pub 2018.
Keung EZ, Chiang YJ, Voss RK, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44(1):170-177. e-Pub 2017.
Cancer Genome Atlas Research Network [Adbani R, Byers LA, Chin L, Lazar A, Lu Y, Mills GB, Roszik J, Torres KE, Wang J, address: elizabethdemicco@sinaihealthsystemca WJE, Research Network CGA. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171(4):950-965.e28, 2017. e-Pub 2017. PMID: 29100075.
Voss RK, Chiang YJ, Torres KE, Guadagnolo BA, Mann GN, Feig BW, Cormier JN, Roland CL. Adherence to national comprehensive cancer network guidelines is associated with improved survival for patients with stage 2A and stages 2B and 3 extremity and superficial trunk soft tissue sarcoma. Ann Surg Oncol 24(11):3271-3278, 2017. e-Pub 2017. PMID: 28741122.
May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Al Sannaa GA, Bhalla AD, Wang WL, Lazar AJ, Torres KE. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther 8(10):816-826, 2017. e-Pub 2017. PMID: 29099264.
Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2017. e-Pub 2017.
Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Hsu FJ, Wang R, Li S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Letter:216-223, 2017. e-Pub 2017. PMID: 28652021.
Ikoma N, Torres KE, Lin HY, Ravi V, Roland CL, Mann GN, Hunt KK, Cormier JN, Feig BW. Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. J Surg Oncol 116(3):313-319, 2017. e-Pub 2017.
Dodd RD, Lee CL, Overton T, Huang W, Eward WC, Luo L, Ma Y, Ingram DR, Torres KE, Cardona D, Lazar AJ, Kirsch DG. NF1+/- Hematopoietic cells accelerate malignant peripheral nerve sheath tumor development without altering chemotherapy response. Cancer Res 77(16):4486-4497, 2017. e-Pub 2017.
Panse G, Leung CH, Ingram DR, Wani K, Torres KE, Lin H, Lazar AJ, Wang WL. The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumors. Histopathology 70(6):946-953, 2017. e-Pub 2017. PMID: 27992966.
Watson KL, Al Sannaa GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, Cormier JN, Hunt KK, Feig BW, Ashleigh Guadagnolo B, Bishop AJ, Wang WL, Slopis JM, McCutcheon IE, Lazar AJ, Torres KE. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg 126(1):319-329, 2017. e-Pub 2017.
Al Sannaa GA, Watson KL, Wang WL, Fuller GN, McCutcheon I, Torres KE, Lazar AJ. Sarcoma Brain Metastases: 28 years of experience at a single institution. Ann Surg Oncol 23(Suppl 5):962-967, 2016. e-Pub 2016. PMID: 27646022.
de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Åman P, Torres KE, Lev D, Nielsen TO, Bovée JV, Lazar AJ, Somaiah N. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest 96(8):885-94, 2016. e-Pub 2016.
Roland CL, May CD, Watson KL, Al Sannaa GA, Dineen SP, Feig R, Landers S, Ingram DR, Wang WL, Guadagnolo BA, Feig B, Hunt KK, Cormier JN, Lazar AJ, Torres KE. Analysis of clinical and molecular factors impacting oncologic outcomes in undifferentiated pleomorphic sarcoma. Ann Surg Oncol 23(7):2220-8, 2016. e-Pub 2016. PMID: 26847678.
Cleven AH, Al Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29(6):582-90, 2016. e-Pub 2016.
Roland CL, Boland GM, Demicco EG, Lusby K, Ingram D, May CD, Kivlin CM, Watson K, Al Sannaa GA, Wang WL, Ravi V, Pollock RE, Lev D, Cormier JN, Hunt KK, Feig BW, Lazar AJ, Torres KE. Clinical observations and molecular variables of primary vascular leiomyosarcoma. JAMA Surg 151(4):347-54, 2016. e-Pub 2016. PMID: 26629783.
Kivlin CM, Watson KL, Al Sannaa GA, Belousov R, Ingram DR, Huang KL, May CD, Bolshakov S, Landers SM, Kalam AA, Slopis JM, McCutcheon IE, Pollock RE, Lev D, Lazar AJ, Torres KE. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biol Ther 17(2):129-38, 2016. e-Pub 2016. PMID: 26650448.
Bishop AJ, Zagars GK, Torres KE, Hunt KK, Cormier JN, Feig BW, Guadagnolo BA. Combined modality management of retroperitoneal sarcomas: a single institution series of 121 patients. Int J Radiat Oncol Biol Phys 93(1):158-65, 2015. e-Pub 2015. PMID: 26130233.
Brudvik KW, Patel SH, Roland CL, Conrad C, Torres KE, Hunt KK, Cormier JN, Feig BW, Aloia TA, Vauthey JN. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg 19(8):1476-83, 2015. e-Pub 2015. PMID: 26001368.
Keung E, Akdemir K, Al Sannaa GA, Garnett J, Lev D, Torres KE, Lazar A, Rai K, Chin L. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J Clin Investigation 125(8):2965-78, 2015. e-Pub 2015.
Demicco EG, Harms PW, Patel RM, Smith SC, Ingram D, Torres KE, Carskadon SL, Camelo-Piragua S, McHugh JB, Siddiqui J, Palanisamy N, Lucas DR, Lazar AJ, Wang WL. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol 143(5):672-82, 2015. e-Pub 2015.
Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W, Lev D, Pollock R, Wang WL, Feig B. Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes. Ann Surg Oncol 22(4):1068-72, 2015. e-Pub 2015.
Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, Hornick JL, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology 66(5):627-38, 2015. e-Pub 2015. PMID: 24889065.
Dineen SP, Roland CL, Feig R, May C, Zhou S, Demicco E, Al Sannaa GA, Ingram D, Wang WL, Ravi V, Guadagnolo A, Lev D, Pollock RE, Hunt K, Cormier J, Lazar A, Feig B, Torres KE. Radiation-Associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions. Ann Surg Oncol. e-Pub 2015.
Zhang P, Yang X, Ma X, Ingram DR, Lazar AJ, Torres KE, Pollock RE. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer 14(1):55, 2015. e-Pub 2015. PMID: 25890085.
Peng X, Li W, Johnson WD, Torres KE, McCormick DL. Overexpression of lipocalins and pro-inflammatory chemokines and altered methylation of PTGS2 and APC2 in oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide. PLoS One 1(e0116285), 2015. e-Pub 2015.
Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, Freemantle SJ, Dmitrovsky E. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer 15:886, 2015. e-Pub 2015. PMID: 26555296.
May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, Al Sannaa GA, Vu T, Han L, Zhang Y, Kivlin CM, Bolshakov S, Kalam AA, Liu J, Zhou F, Broccoli D, Wang WL, Lazar AJ, Pollock RE, Lev D, Torres KE. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer 15:901, 2015. e-Pub 2015. PMID: 26573603.
Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, Cormier JN, Pisters PW, Lev DC, Pollock RE, Feig BW, Hunt KK. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol 21(8):2499-505, 2014. e-Pub 2014. PMID: 24639192.
Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, Vollan HK, Papaemmanuil E, Koss H, Bunney TD, Hardy C, Joseph OR, Martin S, Mudie L, Butler A, Teague JW, Patil M, Steers G, Cao Y, Gumbs C, Ingram D, Lazar AJ, Little L, Mahadeshwar H, Protopopov A, Al Sannaa GA, Seth S, Song X, Tang J, Zhang J, Ravi V, Torres KE, Khatri B, Halai D, Roxanis I, Baumhoer D, Tirabosco R, Amary MF, Boshoff C, McDermott U, Katan M, Stratton MR, Futreal PA, Flanagan AM, Harris A, Campbell PJ. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 46(4):376-9, 2014. e-Pub 2014. PMID: 24633157.
Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74(6):1645-50, 2014. e-Pub 2014. PMID: 24448245.
Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR, Goydos JS, Gorski DH. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PLoS One 9(1):e81126, 2014. e-Pub 2014. PMID: 24404125.
Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres KE, Colombo C, Peng T, Lusby K, Ingram D, Hornick JL, Wang WL, Ravi V, Lazar AJ, Lev D, Pollock RE. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer 119(10):1868-77, 2013. e-Pub 2013. PMID: 23401071.
Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20(4):1267-74, 2013. e-Pub 2013. PMID: 23224828.
Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D. Targeting the PI3K/mTOR Axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther 11(8):1758-69, 2012. e-Pub 2012. PMID: 22848094.
Torres KE, Lazar A, Pollock R, Lev A. Angiosarcoma: A frequently recurrent and highly metastatic malignancy. Eur J Clin Med Oncol 4(2):73-81, 2012. e-Pub 2012.
Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, Peng T, Bovée JV, Wang WL, Lev D, Lazar AJ. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol 25(2):212-21, 2012. e-Pub 2012. PMID: 22020193.
Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D. Pleomorphic liposarcoma: Clinical observations and molecular variables. Cancer 117(23):5359-69, 2011. e-Pub 2011. PMID: 21598240.
Lahat G, Zhang P, Zhu QS, Torres KE, Ghadimi M, Smith KD, Wang WL, Lazar AJ, Lev D. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology 59(3):556-561, 2011. e-Pub 2011. PMID: 22034893.
Torres KE, Liu J, Young E, Huang KL, Ghadimi M, Lusby K, Lazar AJ, Lev D. Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer. Histopathology 59(1):156-9, 2011. e-Pub 2011. PMID: 21771036.
Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 17(12):3943-55, 2011. e-Pub 2011. PMID: 21540237.
Lopez G, Torres KE, Lev D. Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: Potential implications for the treatment of a therapeutic-resistant malignancy. Autophagy 7(4):440-1. e-Pub 2011.
Lopez G, Torres KE, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, McConkey D, Lev D. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res 71(1):185-96, 2011. e-Pub 2011. PMID: 21084276.
Ylipää A, Hunt KK, Yang J, Lazar AJ, Torres KE, Lev DC, Nykter M, Pollock RE, Trent J, Zhang W. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer 117(2):380-9, 2011. e-Pub 2011. PMID: 20818650.
Wang S, Ren W, Liu J, Lahat G, Torres KE, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD, Lev D. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 16(9):2591-604, 2010. e-Pub 2010. PMID: 20406839.
Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J, Torres KE, Langley RR, Lazar AJ, Hung MC, Lev D. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 5(4):e10105, 2010. e-Pub 2010. PMID: 20419128.
Torres KE, Burd RS. Recent nationwide trends in the utilization of pectus repairs in children. J Surg Res 137(2):328-329, 2007. e-Pub 2007.
Gorski D, Schell SR, Kounalakis N, Torres KE, Barnard NJ, Goydos JS, Chen S. Elevated metabotropic glutamate receptor expression: a novel finding in invasive breast cancer. J Surg Res 130(2):164, 2006. e-Pub 2006.
Gold JP, Torres KE, Maldarelli W, Zhuravlev I, Condit D, Wasnick J. Improving outcomes in coronary surgery: the impact of echo-directed aortic cannulation and perioperative hemodynamic management in 500 patients. Ann Thorac Surg 78(5):1579-85, 2004. e-Pub 2004. PMID: 15511435.
Gold JP, Wasnick J, Maldarelli W, Zhuraavlev I, Torres KE, Condit D. Selective use of off-pump coronary bypass surgery reduces mortality and neurologic morbidity associated with high-risk coronary bypass surgery: a 400-case comparative experience. Heart Surg Forum 7(6):e562-8, 2004. e-Pub 2004. PMID: 15769687.
Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres KE, Orr GA, Horwitz SB. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 63(6):1207-13, 2003. e-Pub 2003. PMID: 12649178.
Torres KE, Horwitz SB. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 58(16):3620-6, 1998. e-Pub 1998. PMID: 9721870.
Báez A, Torres KE, Tan EM, Pommier Y, Casiano CA. Expression of proliferation-associated nuclear autoantigens, p330d/CENP-F and PCNA, in differentiation and in drug-induced growth inhibition using two-parameter flow cytometry. Cell Prolif 29(4):183-96, 1996. e-Pub 1996. PMID: 8695747.
Goldwasser F, Bae I, Valenti M, Torres KE, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55(10):2116-21, 1995. e-Pub 1995. PMID: 7743511.
Xiao JF, Ko EY, Smith A, Piras R, Fowler A, Ishaya K, Wang L, Wang B, Paulucci-Holthauzen A, Landers SM, Bhalla AD, Torres KE, Shamsutdinova D, Wani KM, Lazar AJ, Keung EZ, Somaiah N, Nassif Haddad EF, Guarnerio J. LPAR4 mediates adaptation to interferon-induced stress in soft tissue sarcoma. Science Advances.

Invited Articles

Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin N Am 25(4):775-88, 2016. e-Pub 2016. PMID: 27591498.
Zhang P, Torres KE, Liu X, Liu CG, Pollock RE. An Overview of Chromatin-Regulating Proteins in Cells. Curr Protein Pept Sci 17(5):401-10, 2016. e-Pub 2016. PMID: 26796306.

Professional Educational Materials

Torres KE, Zhu Q, Lev D. Targeting the PI3K/AKT Pathway in UPS/MFH. 8,5. Electronic Sarcoma Update Newsletter (ESUN): http://sarcomahelp.org/research_center/UPS-MFH_study.html, 2011.
Torres KE, Pollock RE. Alveolar Soft Part Sarcoma. 7, 6. Electronic Sarcoma Update Newsletter (ESUN): http://sarcomahelp.org/learning_center/asps.html, 2010.
Moufflet A, Moore J, Panarelli A, Madrid D, Schimmrich K, Pevzner L, Torres KE, Angel M, Zahtz E, Sorbellini M, Koppolu S, Cuevas J, Frogel D, Grinspan Z, Spector J, Hirsh D, Vouyiouklis M. AECOM Dissector Online. Chapter 3, Section 2, 7, & 8, http://storm.aecom.yu.edu/virtualDissector, 2001.

Abstracts

Malik N, Keung EZ, Scally CP, Hunt KK, Torres KE, Lillemoe HA, Roland CL, Lyu HG. The Impact of Vascular Management on Complications in Patients with Retroperitoneal Leiomyosarcoma. Poster presentation at the 2025 Annual Academic Surgical Congress (ASC), Las Vegas, NV. e-Pub 2025.
Elmorsi R, Camacho L, Krijgh DD, Lyu H, Roubaud MS, Torres KE, Lewis VO, Roland CL, Mericli AF. Extremity Soft Tissue Sarcoma Reconstruction Nomograms (SARCON): A Clinicoradiomic, Machine Learning-Powered Predictor of Postoperative Outcomes. TMC AI Summit, Houston, TX. e-Pub 2025.
Gu Y, Wong J, Landers SM, Bhalla A, Scheet P*, Torres KE*. Optimizing Sequencing Depth for Reliable ctDNA Analysis in Plasma Samples Using Down-Sampling Strategies. 2024 American Society of Human Genetics (ASHG) Annual Meeting, Denver CO. e-Pub 2024.
Malik N, Yj C, Keung E, Haddad EN, Peterson S, Nguyen S, Torres KE, Hunt K, Bishop A, Guardado A, Somaiah N, Roland C, Scally C, Lyu H. Health-Related Quality of Life in Patients With Resectable Retroperitoneal Dedifferentiated Liposarcoma (DDLPS) Treated with Neoadjuvant Checkpoint Blockade in a Randomized Phase II Clinical Trial. Accepted for Poster presentation at the 2024 Connective Tissue Oncology Society (CTOS) Annual Meeting, San Diego, CA. e-Pub 2024.
Rajkot N, Gonzalez J, Holtsmith S, Lillemoe HA, Scally C, Torres KE, Hunt K, Keung E, Roland C, Katz M, Lyu H. The Development and Evaluation of a Synoptic Operative Report for Patients Undergoing Surgery for Soft Tissue Sarcoma. Accepted for Poster presentation at the 2024 Connective Tissue Oncology Society (CTOS) Annual Meeting, San Diego, CA. e-Pub 2024.
Landers SM, Bhalla AD, Rodriguez-Aguayo C, Keung E, Scally C, Roland C, Hunt K, Lyu H, Lillemoe HA, Guadagnolo A, Lazar A, McCutcheon I, Livingston JA, Farooqi A, Torres KE. Treatment of Malignant Peripheral Nerve Sheath Tumor with Bromodomain Extra Terminal Inhibitor (Beti) in Combination with Radiotherapy. Accepted for Poster presentation at the 2024 Connective Tissue Oncology Society (CTOS) Annual Meeting, San Diego, CA. e-Pub 2024.
Munnangi P, Gingrich A, Chiang Y, Lyu H, Lillemoe H, Scally C, Keung E, Roland C, Hunt K, Torres KE. Impact of Demographics and Socioeconomic Factors on Likelihood of Receiving Surgery for Neurofibromatosis 1 (NF1)-associated Malignant Peripheral Nerve Sheath Tumors (MPNST). Accepted for Oral ePoster Presentation at the 2024 American Collage of Surgeons (ACS) Annual Meeting, San Francisco, CA. e-Pub 2024.
Oliveras A*, Ramirez A*, Nguyen G*, Bhalla AD, Landers SM, Rodriguez-Aguayo C, Torres KE, *Contributed Equally. Inhi-BET-ing Bromodomain Containing Protein 4 (BRD4) to Improve Radiation Therapy Response in Malignant Peripheral Nerve Sheath Tumors. Accepted for Poster Presentation at the 2024 U54 Partnership Summer Research for Excellence in Cancer Research, San Juan, Puerto Rico. e-Pub 2024.
Ramirez A, Oliveras A, Nguyen G, Bhalla AD, Landers SM, Rodriguez-Aguayo C, Torres KE. Sensitizing Malignant Peripheral Nerve Sheath Tumors to Radiation Therapy by Inhibiting Bromodomain Proteins. Accepted for Poster Presentation at the 2024 CATALYST Training Program Symposium, Houston, TX. e-Pub 2024.
Gingrich A, Landers S, Bhalla A, Keung EZ, Scally CP, Roland CL, Hunt KK, Guadagnolo A, Slopis J, McCutcheon I, Livingston JA, Farooqi A, Torres KE. Role of Bromodomain Extra Terminal Inhibitor (BETi) in Combination with Radiotherapy for the Treatment of Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis Type 1 Patients. Accepted for Poster presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA. e-Pub 2024.
Munnangi P, King BL, Chiang YS, Conley AP, Araujo DM, Livingston A, Ludwig JA, Nakazawa M, Haddad EFN, Ravi V, Ratan R, Zarzour MA, Patel S, Torres KE, Somaiah N. Systemic Therapy In NF-1 Associated Malignant Peripheral Nerve Sheath Tumors (MPNST). Accepted for Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. e-Pub 2024.
Denu RA, Segura RL, Farooqi AS, Ingram D, Wani KM, Cai Y, Torres KE, Keung EZ, Roland CL, Somaiah N, Ying H, Huse JT, Rai K, Conley AP, Patel S, Wang WL, Lazar AJ, Haddad EFN. Impact of ATRX Loss on Survival and Immune Microenvironment in Multiple Sarcoma Subtypes. Accepted for Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. e-Pub 2024.
Gingrich A#, Montgomery AE#, Munnangi P, Landers S, Wangsiricharoen S, Bhalla A, Lin PP, Lewis VO, Moon BS, Satcher R, Frink SJ, Shreyaskumar S, Lyu H, Lillemoe H, Scally C, Keung E, Roland CL, Hunt KK, Slopis J, McCutcheon I, Lazar A, Wang WL, Bird JE, Yu W, Eberlin LS*, Torres KE*, #Co-First authors, *Co-Senior authors. P64: MasSpec Pen Technology for Molecular Identification of MPNST Surgical Margin Assessment. Accepted for Oral presentation at the 2024 Society of Surgical Oncology (SSO) Annual Meeting, Atlanta, GA. e-Pub 2024.
Montgomery AE, Munnangi P, Gingrich A, Landers S, Wangsiricharoen S, Bhalla A, Lin PP, Lewis VO, Moon BS, Shreyaskumar S, Lyu H, Lillemoe H, Scally C, Keung E, Roland CL, Hunt KK, McCutcheon I, Bird JE, Yu W, Eberlin LS*, Torres KE*, *Co-Senior authors. P59: Evaluation of the MasSpec Pen Technology for Molecular Identification of Sarcomas and Surgical Margin Assessment. Accepted for oral presentation at the 2024 Society of Surgical Oncology (SSO) Annual Meeting, Atlanta, GA. e-Pub 2024.
Chatterjee B, Kochat V, Satpati S, Landers SM, Bhalla AD, Torres KE, Rai K. Epigenome Dysregulation in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. 2024 Cancer Neuroscience Symposium, Houston, TX. e-Pub 2024.
Bishop AJ, Mitra D, Farooqi A, Hempel C, Bagchi C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin R, Torres KE, Hunt K, Scally C, Satcher R, Bird J, Lin P, Moon B, Lewis V, Roland C, Guadagnolo BA. How Should Radiation Therapy be Incorporated Into The Multidisciplinary Management of Soft Tissue Sarcomas Following an Unplanned Excision?. Accepted for Oral presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Farooqi A, Yoder A, Mitra D, Scally C, Moon B, Lin P, Goepfert R, Torres KE, Bird J, Hunt K, Lewis V, Roland C, Guadagnolo BA. How Should Radiation Therapy be Incorporated Into The Multidisciplinary Management of Soft Tissue Sarcomas Following an Unplanned Excision?. Accepted for Oral presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Lillemoe HA, Hunt K, Subramaniam A, Keung EZ, Roland C, Torres KE, Lyu H, Scally C, Mitra D, Farooqi A, Bishop AJ, Guadagnolo BA, Ravi V. Primary Breast Angiosarcoma: Clinical and Pathological Features and Impact on Outcomes. Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Tomczak K, Patel SS, Peterson C, Landers S, Bhalla AD, Landry JP, Callahan C, Lazar AJ, McCutcheon I, Slopis JM, Livingston JA, Guadagnolo BA, Zhang D, Wong J, Keung EZ, Scally C, Roland C, Hunt K, Gu J, Scheet P, Wang L, Rai K, Torres KE. Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients with Neurofibromatosis Type 1 (NF1). Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Bishop AJ, Mitra D, Farooqi A, Hempel C, Bagchi C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin R, Torres KE, Hunt K, Scally C, Satcher R, Bird J, Lin P, Moon B, Lewis V, Roland C, Guadagnolo BA. Long-Term Disease Outcomes, Late Toxicity, and Function Following Hypofractionated Preoperative Radiation Therapy for Patients with Soft Tissue Sarcomas: A Hyport-STS Update. Accepted for Oral presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Gingrich AA, Beird H, Chu R, Traweek R, Cope B, Keung EZ, Scally C, Hunt K, Torres KE, MD, Roland C, Futreal PA, Co-Author: Bishop AJ, Guadagnolo BA, Mitra D, Farooqi A, Araujo DM, Zarzour M, Livingston JA, Conley AP, Patel SS, Ravi V, Somaiah N, Lazar AJ, Ratan R, Nassif E. Leiomyosarcoma Intratumoral Macrophage Infiltrates are Associated with Distinct Clinical and Genomic Presentations. Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Lillemoe HA, Hunt K, Subramaniam A, Keung EZ, Roland C, Torres KE, Lyu H, Scally C, Mitra D, Farooqi A, Bishop AJ, Guadagnolo BA, Ravi V. Leiomyosarcoma Intratumoral Macrophage Infiltrates are Associated with Distinct Clinical and Genomic Presentations. Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Torres KE, Montgomery A, Bird J, Landers S, Fletcher D, Wangsiricharoen S, Lin P, Lewis V, Moon B, Satcher R, Frink S, Shreyaskumar Patel S, Scally C, Keung E, Roland C, Hunt K, McCutcheon I, Wang WL, Yu W, Eberlin L. Evaluation of the Masspec Pen Technology for Molecular Identification of Bone and Soft Tissue Sarcomas and Surgical Margin Assessment. Accepted for oral presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Montgomery A, Bird J, Landers S, Fletcher D, Wangsiricharoen S, Lin P, Lewis V, Moon B, Satcher R, Frink S, Patel SS, Scally C, Keung EZ, Roland C, Hunt K, McCutcheon I, Wang W, Yu W, Eberlin L, Torres KE. Evaluation of the Masspec Pen Technology for Molecular Identification of Bone and Soft Tissue Sarcomas and Surgical Margin Assessment. Accepted for oral presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Dublin, Ireland. e-Pub 2023.
Montgomery AE, Bird JE, Fletcher D, Landers S, Wangsiricharoen S, Wei-Lien W, Wendong Y, Eberlin LS, Torres KE. Application of the MasSpec Pen Technology for Molecular Identification of Human Sarcomas and Surgical Margin Evaluation. Accepted for oral presentation at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, Houston, TX. e-Pub 2023.
Traweek RS, Lazcano R, Cope BM, Bishop AJ, Guadagnolo BA, Ingram DR, Wani K, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Nassif EF, Roland CL. Major Pathologic Response (MPR) Following Neoadjuvant Radiation Therapy (RT) +/- immune-checkpoint Blockade (ICB) is Associated with Improved Survival in Undifferentiated Pleomorphic Sarcoma (UPS). Accepted for oral presentation at the American Radium Society (ARS) Annual Meeting, Lahaina, Maui. e-Pub 2023.
Gingrich A, Torres M, Bonsu NY, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar A, MD, Wang WL, Roland CL, Feig B, Hunt KK, Yu W, Torres KE. Clinical Variables Influencing Outcomes in Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single Institution Study of 95 Surgical Patients. Accepted for oral presentation at the 2023 American Radium Society (ARS) Annual Meeting, Lahaina, Maui. e-Pub 2023.
Gingrich A, Wangsiricharoen S, Torres M, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar A, Wang WL, Roland CL, Feig B, Hunt KK, Yu W, Torres KE. Clinical Variables Influencing Outcomes in Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single Institution Study of 95 Surgical Patients. Accepted for poster presentation at the 2023 Society of Surgical Oncology (SSO) Annual Meeting, Boston, MA. e-Pub 2023.
Munnangi P#, Montgomery AE#, Gingrich A, Landers S, Wangsiricharoen S, Bhalla A, Lin PP, Lewis VO, Moon BS, Shreyaskumar S, Scally C, Keung EZ, Roland CL, Hunt KK, McCutcheon I, Bird JE, Yu W, Eberlin LS*, Torres KE*, #Co-First authors, *Co-Senior authors. 420: Use of the Masspec Pen Technology for Accurate Determination of Surgical Margins of Myxofibrosarcomas (MFS). Accepted for Poster presentation at the 2024 Society of Surgical Oncology (SSO) Annual Meeting, Atlanta, GA. e-Pub 2023.
Nassif E, Liu B, Wang WL, Lazar A, Ingram DR, Wani KM, Duncan S, Tate TJ, Mathew G, Crosby SD, Shaw KR, Zelazowska MA, Feig BW, Torres KE, Hunt KK, Guadagnolo A, Bishop AJ, Futreal A, Wargo J, Somaiah N, McBride K, Roland CL, Keung E. B-Cell Receptor (BCR) Repertoire is a Dynamic Biomarker of Survival in Sarcoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB). Accepted for oral presentation at the Society for Immunotherapy of Cancer, Boston, MA. e-Pub 2022.
Witt RG, Voss RK, Chiang YJ, Sa N, Scally CP, Lin PP, Torres KE, Moon BS, Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. Practice Patterns in the Management of Regional Lymph Node Metastasis in Soft Tissue Sarcoma: A Survey of The Society of Surgical Oncology and Musculoskeletal Tumor Society Membership. Accepted for oral presentation at the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting, Vancouver, BC, Canada. e-Pub 2022.
Traweek RS, Witt RG, Nassif EF, Ajami NJ, Mishra AK, Damania AV, Chelvanambi M, Wang WL, Lazar AJ, Keung EZ, Torres KE, Scally CP, Zhang X, Daniel-MacDougall CR, Wargo JA, Somaiah N, Roland CL. Dietary Fiber Intake is Associated with Increased Tertiary Lymphoid Structures in Dedifferentiated Liposarcoma Following Immune Checkpoint Blockade. Accepted for oral presentation at the Society for Immunotherapy of Cancer, Boston, MA. e-Pub 2022.
Pemberton J, Bhalla A, Landers S, Kochat V, Torres KE. Effects of ZIC1 Enhancer Silencing in Malignant Peripheral Nerve Sheath Tumors. Poster presentation and Winner of the Scientific Poster Competition. Partnership for Careers in Cancer Science and Medicine (PCCSM) Symposium, Houston, TX. e-Pub 2022.
Lyu HG, Lillemoe HA, Chiang YJ, Keung EZ, Nguyen ST, Peterson SK, Torres KE, Hunt K, Feig BW, Bishop AJ, Guadagnolo BA, Somaiah N, Roland CL, Scally C. Health-Related Quality of Life in Patients with Resectable Undifferentiated Pleomorphic Sarcoma Treated with Neoadjuvant Checkpoint Blockade in a Single Institution Randomized Phase II Clinical Trial. Accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. e-Pub 2022.
Keung EZ, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang WL, Guadagnolo BA, Bishop AJ, Hunt K, Feig BW, Bird JE, Lewis VO, Ratan R, Patel S, Zelazowska M, Liu B, McBride K, Wargo JA, Roland CL, Somaiah N. Randomized Phase II Study of Neoadjuvant Checkpoint Blockade for Surgically Resectable Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS): Survival Results after 2 years of Follow-up and Intratumoral B-Cell Receptor (BCR) Correlates. Accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. e-Pub 2022.
Nassif EF, Wu CC, Akdemir K, Witt RG, Traweek R, Cope B, Thirasastr P, Tate T, Mathew G, Crosby S, Chu R, Mohammad M, Shaw K, Davis Ingram D, Wani K, Lazar AJ, Wang WL, Duncan S, B Guadagnolo BA, Bishop AJ, Lewis V, Bird JE, Torres KE, Hunt KK, Feig BW, Scally CP, Ratan R, Patel SP, Benjamin R, Satcher R, McBride K, Fridman WH, Wistuba I, Futreal A, Wargo JA, Somaiah N, Roland CL, Keung EZ. Antigen Presentation and Processing Pathway is Associated with Early Relapse after Neoadjuvant Immune Checkpoint Blockade (ICB) in Dedifferentiated Liposarcomas (DDLPS). Accepted for oral presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, Montreal, QC Canada. e-Pub 2022.
Kochat V, Chatterjee B, Satpati S, Callahan SC, McLaughlin ME, Dede M, Chou JH, Landers SM, Lazcano Segura RN, Singh AK, Lazar A, Li W, Hart T, Rai K, Torres KE. Dependency of PRC2-Mutant MPNSTS on RNA Exosome Machinery. Oral Presentation at the TRANSCEND Symposium, Houston, TX. e-Pub 2022.
Landry J, Kochat V, Satpati S, Bhalla AD, Landers SM, Parker LA, Miller TM, Ingram D Keung E, Scally C, Roland CL, Hunt KK, Slopis J, McCutcheon I, Boudreau B, Wilson-Robles H, Lazcano Segura RN, Lazar AJ, Wiener D, Davis B, Rai K, Wustefeld-Janssens B, Torres KE. Comparative Clinical Genomic And Epigenomic Study Of Human And Canine Malignant Peripheral Nerve Sheath Tumors (MPNST). Poster Presentation at the TRANSCEND Symposium, Houston, TX. e-Pub 2022.
Mitra D, Farooqi A, Hempel C, Dorber C, Mathai R, Wang WL, Ratan R, Torres KE, Somaiah N, Hunt KK, Scally CP, Keung EZ, Satcher R, Bird JE, Lin P, Moon B, Lewis V, Roland CL, Bishop AJ, Guadagnolo BA. Prospective Single-Arm Controlled Trial of 3-Week-Course Hypofractionated Preoperative Radiotherapy for Soft Tissue Sarcoma of the Extremity or Trunk. Accepted for oral presentation at the 2021 Connective Tissue Oncology Society (CTOS), Virtual Meeting. e-Pub 2021.
Erstad DJ, Chiang YJ, Witt RG, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Accepted for poster presentation at the 2021 Western Surgical Society Annual Meeting, Indian Wells, CA. e-Pub 2021.
Nassif EF, Roland CL, Thirasastr P, Scally CP, Zarzour A, Valenzuela R, Torres KE, Hunt KK, Feig BW, Wang WL, Lazar AJ, Somaiah N, Keung EZ. Surgical Outcomes of Patients with Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcomas Treated with Palbociclib. Accepted poster presentation at the 2021 Connective Tissue Oncology Society (CTOS), Virtual Meeting. e-Pub 2021.
Witt RG, Chiang YJ, Erstad DJ, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma – A Single Center Experience of 86 Consecutive Cases. Accepted for oral presentation at the 2021 Connective Tissue Oncology Society (CTOS), Virtual Meeting. e-Pub 2021.
Landry JP, Kochat V, Landers SM, Bhalla AD, Lazcano R, Parker L, Miller T, Ingram DR, Wiener D, Davis B, Boudreau B, Wang WL, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Slopis JM, Wilson-Robles H, Lazar A, Rai K, Wustefeld-Janssens B, Torres KE. Comparative Review of Human and Canine Peripheral Nerve Sheath Tumors. Accepted for oral presentation at the 2021 Connective Tissue Oncology Society (CTOS), Virtual Meeting. e-Pub 2021.
Tomczak KJ, Peterson CB, Callahan SC, Landers SM, Terranova CJ, Serrao GSB, Bhalla AD, Landry JP, Mulder ZA, Yeagley MG, Bolshakov S, Ayush R, Gardenhire EL, Ingram D, Lazar A, Wang WL, McCutcheon IE, Slopis J, Rai K, Torres KE. DNA Methylation-Based Biomarkers for MPNST Detection in Patients with Neurofibromatosis Type 1. Poster presentation at the 2020 American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA. e-Pub 2020.
Stark AP, Bathala T, Hunt KK, Torres KE, Keung EZ, Scally CP, Feig BW, Roland CL. Preoperative Localization of Non-Palpable Primary and Recurrent Soft Tissue Sarcoma Using Magseed ®. Accepted for poster presentation at the 2020 Society of Surgical Oncology (SSO) Annual Meeting, San Diego, CA. e-Pub 2020.
Landry JP, Yeagley M, Ingram DR, Chiang YJ, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Cormier JN, Torres KE. Clinical Variables Influencing Outcome for Alveolar Soft Part Sarcoma: Results from 152 Patients at a Single Institution. Accepted for poster presentation at the 2020 Society of Surgical Oncology (SSO) Annual Meeting, Boston, MA. e-Pub 2020.
Stark AP, Rajkot N, Ikoma N, Chiang YJ, Wang WL, Roland CL, Torres KE, Zarzour MA, Ravi V, Hunt KK, Feig BW. Evaluation of Response to Preoperative Therapy and Outcome in Primary Retroperitoneal Leiomyosarcoma. Accepted for poster presentation at the 2020 Society of Surgical Oncology (SSO) Annual Meeting, San Diego, CA. e-Pub 2020.
Keung EZ, Rajkot N, Cormier JN, Torres KE, Somaiah N, Hunt KK, Feig BW, Ikoma N, Roland CL. The Impact of Surveillance Interval Following Resection of Primary Well Differentiated Liposarcoma of the Retroperitoneum. Accepted for poster presentation at the South Texas Chapter of the American College of Surgeons Annual Meeting, Houston, TX. e-Pub 2020.
Roland CL, Keung EZ, Lazar AJ, Wang WL, Cormier JN, Guadagnolo BA, Bishop AJ, Mujtaba B, Lin HY, Torres KE, Hunt KK, Feig BW, Bird JE, Lewis VO, Patel SR, Wargo JA, Somaiah N. Phase II Study of Neoadjuvant Checkpoint Blockade in Patients with Surgically Resected Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma-Preliminary Safety Data. Poster Presentation at 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan. e-Pub 2019.
Keung EZ, Rajkot N, Cormier JN, Torres KE, Hunt KK, Feig BW, Ikoma N, Roland CL. The Impact of Surveillance Interval Following Resection of Primary Well Differentiated Liposarcoma of The Retroperitoneum. Poster Presentation at 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan. e-Pub 2019.
Davis CH, Asare EA, Sabir S, Roland CL, Torres KE, Hunt KK, Cormier JN, Feig BW. Management and Outcomes of Patients with Fistulized Mesenchymal Tumors. Poster presentation at the 2019 Society of Surgical Oncology (SSO) Annual Meeting, San Diego, CA. e-Pub 2019.
Landry JP, Schertz K, Chiang YJ, Roland CL, Keung EZ, Scally CP, Wang WL, Lazar AJ, Feig BW, Hunt KK, Slopis JM, McCutcheon IE, Torres KE. Cancer Risk in Patients with Neurofibromatosis Type 1. Poster presentation at the 2019 Society of Surgical Oncology (SSO) Annual Meeting, San Diego, CA. e-Pub 2019.
Keung EZ, Asare EA, Chiang YJ, Prakash LR, Rajkot N, Roland CL, Torres KE, Cormier JN, Hunt KK, Feig BW, Lee JE, Katz MHG, Tzeng CD. Postoperative Pancreatic Fistula and Morbidity After Distal Pancreatectomy for Non-Pancreas Retroperitoneal Tumor Resection. Poster presentation at the 2019 Society of Surgical Oncology (SSO) Annual Meeting, San Diego, CA. e-Pub 2019.
Kochat V, Raman A, Landers S, Terranova C, C-C W, Mao X, Ingram D, Mulder Z, Yeagley M, Beird H, Bhalla A, Slopis J, McCutcheon I, Zhang J, Futreal P, W-L W, Lazar AJ, Rai K, Torres KE. Chromatin State Transitions Associated with PRC2 Functional Loss Drive a De-Differentiated Phenotype in Malignant Peripheral Nerve Sheath Tumors. Presented at 2018 Connective Tissue Oncology Society (CTOS) Annual Meeting, Rome, Italy. e-Pub 2018.
Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig B, W-L W, Lazar AJ, Moon B, Roland C, Guadagnolo BA. Young Patients with Desmoid Fibromatosis Have High Rates of Local Recurrence: Is It Time to Rethink Treatment Strategies in This Subset?. Presented at 2018 Connective Tissue Oncology Society (CTOS) Annual Meeting, Rome, Italy. e-Pub 2018.
Sandler G, Y-J C, Cormier J, Hunt K, Lazar AJ, Lynch P, Roland C, Torres KE, You YN, Feig B. A Clinical Comparison of Familial (APC Mutated) vs Sporadic (CTNB1 Mutated) Desmoid Tumors. Presented at 2018 Connective Tissue Oncology Society (CTOS) Annual Meeting, Rome, Italy. e-Pub 2018.
Ikoma N, W-L W, Roland C, Torres KE, Vinod R, Hunt K, Cormier J, Feig B. Evaluation of Treatment Response to Preoperative Therapy in Retroperitoneal Leiomyosarcoma. Presented at 2018 Connective Tissue Oncology Society (CTOS) Annual Meeting, Rome, Italy. e-Pub 2018.
Kochat V, Raman A, Landers SM, Teranova C, Wu CC, Mao X, Ingram D, Mulder ZA, Yeagley MG, Bierd H, Bhalla A, McCutcheon I, Slopis J, Zhang J, Futreal A, Wang WL, Lazar A, Rai K, Torres KE. Oncogenic Role of EZH2 in the Pathogenesis of Malignant Peripheral Nerve Sheath Tumors with Functionally Inactive Polycomb Repressor Complex 2. Accepted for poster presentation at the 2018 Keystone Symposia Conference on Cancer Epigenetics: New Mechanisms, New Therapies, Breckenridge, CO. e-Pub 2018.
Grotz TE, Schertz K, Yeagley M, Guadagnolo AB, Somaiah N, Hunt KK, Cormier JN, Feig B, Wang WL, Lazar A, Torres KE, Roland CL. Evaluation of Neoadjuvant Therapy in the Treatment of Myxoid Liposarcoma. Presented at the 2017 Connective Tissue Oncology Society (CTOS) Annual Meeting, Maui, HI. e-Pub 2017.
Ikoma N, Roland CL, Chiang YJ, Torres KE, Hunt KK, Somaiah N, Cormier JN, Feig BW. Timing and Extent of Surgical Resection for Recurrent Retroperitoneal Well-Differentiated Liposarcoma. Accepted for Poster Presentation at the 2017 Society of Surgical Oncology (SSO) Annual Meeting, Seattle, WA. e-Pub 2017.
Holder AM, Chiang K, Torres KE, Cormier J, Ravi V, Mann GN, Hunt KK, Feig BW, Roland C. Identifying Patients Most Likely to Benefit from Salvage Surgery for Recurrent or Metastatic Uterine Leiomyosarcoma. Accepted for Poster Presentation at the 2017 Society of Surgical Oncology (SSO) Annual Meeting, Seattle, WA. e-Pub 2017.
Ikoma N, Roland C, Torres KE, Mann G, Hunt KK, Cormier J, Feig BW. Does Extended Surgical Resection Improve Outcomes in Primary Retroperitoneal Well-Differentiated Liposarcoma?. Accepted for poster presentation at the 2016 Connective Tissue Oncology Society (CTOS) Annual Meeting, Lisbon, Portugal. e-Pub 2016.
Roland CL, Watson K, Chiang YJ, Liang Y, DeRosa N, Mann G, Cormier JN, Hunt KK, Feig BW, Wang WL, Lazar A, Torres KE. Oncologic Outcomes in Patients with Extremity Myxofibrosarcoma (MFS) and Undifferentiated Pleomorphic Sarcoma: A Matched Case-Control Study. Accepted for poster presentation at the 2016 Connective Tissue Oncology Society (CTOS) Annual Meeting, Lisbon, Portugal. e-Pub 2016.
Roland C, Bednarski B, Watson K, Torres KE, Cormier J, Mann GN, Wang W, Lazar A, Somaiah, N, Hunt KK, Feig B. Surgical Management of Patients with Recurrent or Intra-Abdominal Metastatic GIST Following Neoadjuvant Tyrosine Kinase Inhibitor Therapy: Who is Benefiting?. Accepted for Poster Presentation at the 2016 Society of Surgical Oncology (SSO) Annual Meeting, Boston, MA. e-Pub 2016.
Voss R, Cormier J, Chiang YJ, Torres KE, Feig B, Hunt KK, Mann G, Roland CL. Adherence to Stage-Specific Treatment Guidelines for Stages IIA & IIB/III Extremity and Trunk Soft Tissue Sarcoma is Associated with Superior Survival. Accepted for Poster Presentation at the 2016 SSO Meeting, Boston, MA. e-Pub 2016.
Grotz TE, Torres KE, Guadagnolo A, Wang W, Somaiah N, Mann GN, Cormier J, Hunt KK, Feig B. Inguinal Liposarcoma: Is Local Resection Alone Adequate?. Accepted for Poster Presentation at the 2016 Society of Surgical Oncology (SSO) Annual Meeting, Boston, MA. e-Pub 2016.
Ikoma N, Watson KL, Roland CL, Hunt KK, Cormier J, Mann GN, Torres KE, Feig B. Surgical Resection of Recurrent Leiomyosarcoma of the Retroperitoneum May be Beneficial. Accepted for Poster Presentation at the 2016 SSO Annual Meeting, Boston, MA. e-Pub 2016.
Somaiah N, Bhosale P, Lin H, Feig B, Torres KE, Watson K, Roland CL, Conley A, Patel S, Benjamin R. PET/CT Imaging Might Be Superior to Percutaneous Biopsy in Identifying Dedifferentiation in Patients with Well-Differentiated (WDLS)/Dedifferentiated Liposarcoma (DDLS). Accepted for Poster Presentation at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting, Salt Lake City, UT. e-Pub 2015.
Cleven A, Ghada A, Briaire de Bruijn I, Ingram D, van de Rijn M, de Vries M, Watson K, Torres KE, van Duinen S, Hogendoom P, Lazar AJ, Bovee J. Loss of H3k27 Tri-Methylation is a Diagnostic Marker for Malignant Peripheral Nerve Sheath Tumors and an Indicator for an Inferior Survival. Accepted for Poster Presentation at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting, Lake City, UT. e-Pub 2015.
Kivlin CM, Huang KL, Bolshakov S, May CD, Landers SM, Kalam AA, McCutcheon IE, Slopis JM, Lazar AJ, Torres KE. Unraveling the Sensitivity of Malignant Peripheral Nerve Sheath Tumor (MPNST) to Poly (ADP) Ribose Polymerase Inhibition. Accepted for Poster Presentation at the 2015 Children's Tumor Foundation Neurofibromatosis Conference, Monterey, CA. e-Pub 2015.
Somaiah N, Beird H, Shaw K, Want WL, Conley A, Ravi V, Torres KE, Ingram D, Roland C, Subbiah V, Feig B, Lazar A, Benjamin R, Patel S, Hwu P, Futreal A, Meric-Bernstam F, Hong D. Targeted Next Generation Sequencing in Well-Differentiated/Dedifferentiated Liposarcoma (WD/DD LPS): Multiple Gene Amplifications but Few Recurrent Mutations. Accepted for Poster Presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. e-Pub 2015.
de Rosa N, Watson K, Orr WS, Wang WL, Lazar A, Roland C, Cormier J, Hunt KK, Feig B, Torres KE. Determinants of Recurrence and Survival in Myxofibrosarcoma (MFS). Accepted for Poster Presentation at the 2015 Society of Surgical Oncology (SSO) Annual Meeting, Houston, TX. e-Pub 2015.
Roland C, Dineen S, Watson K, Al Sannaa GA, Feig R, May C, Ingram D, Wang WL, Lazar A, Ravi V, Hunt KK, Cormier J, Feig B, Torres KE. Variations in Protein Expression are Associated with Survival Outcomes in Patients with Undifferentiated Pleomorphic Sarcomas. Accepted for Oral Presentation at the 2015 Society of Surgical Oncology (SSO) Annual Meeting, Houston, TX. e-Pub 2015.
Orr WS, Watson K, Feig R, Ikoma N, de Rosa N, Giacco G, Ravi V, Benjamin R, Madewell J, Cormier J, Hunt KK, Roland C, Feig B, Torres KE. Is F-18 Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET/CT) of Value in Soft Tissue Sarcoma Management?. Accepted for Poster Presentation at the 2015 Society of Surgical Oncology (SSO) Annual Meeting, Houston, TX. e-Pub 2015.
Ikoma N, Landers S, Watson K, Al Sannaa GA, Ingram D, Wang WL, Lazar A, Somaiah N, Roland C, Cormier J, Hunt KK, Feig B, Torres KE. Clinicopathologic Comparison of Retroperitoneal Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma. Accepted for Poster Presentation at the 2015 Society of Surgical Oncology (SSO) Annual Meeting, Houston, TX. e-Pub 2015.
Keung E, Lazar A, Akdemir K, Al Sannaa G, Garnett J, Torres KE, Rai K, Chin L. Functional Validation of Kruppel-Like Factor 6 as a Differentially Expressed and Epigenetically Regulated Transcription Factor with Novel Tumor Suppressor Role in Liposarcoma. Accepted for Poster Presentation at the 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting, Berlin, Germany. e-Pub 2014.
Ravi V, Ramesh N, Patnana M, Conley A, Somaiah N, Lazar A, Aroujo D, Torres KE, Ali S, Miller V, Benjamin R, Hwu P, Hunt KK, Patel S, Futreal A. Targeted Sequencing of Leiomyosarcomas in the Clinic: Potential for Target Identification. Accepted for Poster Presentation at the 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting, Berlin, Germany. e-Pub 2014.
Ravi V, Ramesh N, Conley A, Somaiah N, Torres KE, Benjamin R, Wang WL, Hwu P, Patel S, Rohren E. Predicting Survival Using FDG-PET Responses in Patients with Unclassified Sarcoma. Accepted for Poster Presentation at the 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting, Berlin, Germany. e-Pub 2014.
Keung EZ, Rai K, Kadir AC, Al Sannaa G, Garnett J, Torres KE, Lazar AJ, Chin L. Identification of Kruppel-Like Factor 6)KLF6) as a Differently Expressed Transcription Factor and Tumor Suppressor in Well Differentiated and Dedifferentiated Liposarcoma (WDLPS, DDLPS) through Unbiased Epigenetic Approaches. Presentation at the 2014 American College of Surgeons (ACS) Annual Meeting, San Francisco, CA. e-Pub 2014.
Roland C, Watson K, Al Sannaa G, Feig R, May C, Ingram D, Wang WL, Lazar A, Feig B, Hunt KK, Cormier J, Torres KE. Expression and Significance of Microorna-1, -133A, -182 and -183 in Patients with Undifferentiated Pleomorphic Sarcoma (UPS). Accepted for Poster Presentation at the 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting, Berlin, Germany. e-Pub 2014.
Livingston J, Bugano D, Madewell J, Wang WL, Conley A, Ravi V, Araujo D, Tseng W, Feig B, Torres KE, Benjamin R, Patel S, Somaiah N. Assessing Chemotherapy Benefit in Well-Differentiated/De-Differentiated Liposarcoma. Accepted for Poster Presentation at the 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting, Berlin, Germany. e-Pub 2014.
Al Sannaa G, Torres KE, Ingram D, Wang WL, Lazar AJ. Emerging Immunohistochemical Markers for Malignant Peripheral Nerve Sheath Tumor (MPNST). Accepted for Poster Presentation at the 2014 CAP The Pathologists Meeting, Chicago, IL. e-Pub 2014.
Ravi V, Ramesh N, Patnana M, Conley A, Somaiah N, Zarzour M, Ingram D, Little L, Cao Y, Gumbs C, Mahadeshwar H, Protopopov A, Sannaa G, Seth S, Song X, Tang J, Lazar A, Zhang J, Araujo D, Torres KE, Ali S, Miller V, Stephens P, Benjamin R, Hwu R, Patel S, Futreal A. Whole Exome and Targeted Sequencing of Angiosarcomas: Target identification and treatment implications. Accepted for Poster Presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. e-Pub 2014.
Keung E, Rai K, Akdemir K, Al Sannaa G, Garnett J, Torres KE, Lazar A, Chin L. Identification of Kruppel-Like Factor 6 (KLF6) as a Differentially Expressed Transcription Factor in Well Differentiated and Dedifferentiated Liposarcoma (WDLPS, DDLPS) through Unbiased Epigenetic Approaches. Accepted for Podium Presentation at the 21st Annual NESS Surgical Resident and Fellow Research Presentation Day, UMass Memorial Medical Center, Worcester, MA. e-Pub 2014.
Ikoma N, Tseng W, Torres KE, Hunt KK, Cormier JN, Somaiah N, Feig B. Accuracy of Percutaneous Biopsy for Retroperitoneal Liposarcoma. Accepted for Poster Presentation at the 2014 Society of Surgical Oncology (SSO) Annual Meeting, Phoenix, AZ. e-Pub 2014.
Dineen S, May C, Feig R, Hunt KK, Cormier JN, Feig B, Sannaa A, Ingram D, Wang W, Lazar A, Ravi V, Torres KE. Radiation-associated Unclassified Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes compared to Sporadic Lesions. Accepted for Oral Presentation at the 2014 Society of Surgical Oncology (SSO) Annual Meeting, Phoenix, AZ. e-Pub 2014.
Ikoma N, Chiang Y, Cormier JN, Torres KE, Hunt KK, You Y, Feig B. Spindle Cell Tumors of the Colon and Rectum. Accepted for Poster Presentation at the 2014 Society of Surgical Oncology (SSO) Annual Meeting, Phoenix, AZ. e-Pub 2014.
Kivlin CM, Ma XY, Ingram D, Al Sannaa GA, Feng Y, May C, Bolshakov S, McCutcheon I, Slopis J, Lev D, Lazar AJ, Torres KE. BMN 673, A novel portent PARP inhibitor for the treatment of Malignant Peripheral Nerve Sheath Tumor (MPNST). Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Ravi V, Ramesh N, Somaiah N, Leja MJ, Conley AP, Ludwig J, Araujo DM, Taylor S, Torres KE, Wang WL, Hunt KK, Reardon M, Benjamin R, Patel S. Cardiac Angiosarcoma: Clinical Features and Treatment Outcomes. Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Al Sannaa G, Ingram D, Unlu O, Slopis J, McCutcheon I, Torres KE, Lazar A. The Impact of Neurofibromatosis Type 1 Status on Malignant Peripheral Nerve Sheath Tumors Patient Outcome. Accepted for Poster Presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Bill K, Garnett J, Creighton C, Ma X, Meaux I, Nguyen T, Ingram D, Bolshakov S, Belousov R, Pollock R, Lev D, Torres KE, Lazar AJ. Integrated Anaylsis of the Molecular Deregulations of the MDM2:P53. Accepted for Oral Presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Ma X, Kivlin CM, May C, Uzunparmak B, Han L, Zhou G, Ingram D, Al Sannaa GA, Garnett J, Bolshakov S, McCutcheon I, Slopis J, Lev D, Lazar AJ, Torres KE. Inhibition of AXL Enhances the Sensitivity of Malignant Peripheral Nerve Sheath Tumors to MEK Inhibition. Accepted for Poster Presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Demicco E, Lusby K, Ingram D, Kivlin C, May C, Al Sannaa G, Vinod R, Lazar A, Cormier J, Hunt K, Feig B, Pollock R, Lev D, Torres KE. Immunohistochemical and Clinical Examination of Vascular Leiomyosarcoma Outcomes. Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Garnett J, Bill K, Shen L, Qiu P, Creighton C, Ingram D, Abbas G, Bolshakov S, Ma XY, Kivlin C, May C, Pollock R, Lev D, Torres KE, Lazar AJ. Identification of Signaling Changes and Potential Combination Therapies with MDM2 Inhibition in Dedifferentiated Liposarcoma Cells. Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Somaiah N, Ingram D, Liu J, Bolshakov S, Nguyen T, de Graaff M, Szuhai K, Aman P, Torres KE, Lev DC Nielsen TO, Bovee J, Lazar AJ. Establishment and Characterization of a New Human Myxoid Liposarcoma Cell Line (Dl-221) with the Fus-Ddit3 Translocation. Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Kivlin CM, Ma XY, Zhu QS, Belousov R, Ingram D, Al Sannaa GA, May C, Garnett J, Bolshakov S, McCutcheon I, Slopis J, Pollock RE, Lev D, Lazar AJ, Torres KE. Downregulation of ERCC6 a Potential Mechanism for the Effect of PARP Inhibition in Malignant Peripheral Nerve Sheath Tumor (MPNST). Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Demicco EG, Savannah K, Lusby K, Young ED, Ingram D, Bailey M, Montgomery K, Hornick J, van de Rijn M, Deavers M, Lev DC, Torres KE, Wang WL, Lazar AJ. Diagnostic Utility of Innumohistochemical Markers in Soft Tissue and Uterine Leiomyosarcoma is Limited in Poorly Differentiated Tumors. Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
May CD, Ma X, Zhou F, Feig R, Ingram D, Al Sannaa GA, Kivlin C, Garnett J, Bolshakov S, Lazar AJ, Torres KE. Combination of IGF1R Inhibition with PI3K/mTOR Blockade for the Treatment of Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma. Accepted for poster presentation at the 2013 Connective Tissue Oncology Society (CTOS) Annual Meeting, New York, NY. e-Pub 2013.
Boland G, Demicco EG, Lusby K, Ingram D, Palmer JD, Lazar AJ, Cormier J, Hunt K, Pollock RE, Lev D, Torres KE. Vascular Leiomyosarcomas: Clinical Observations and Molecular Variables. Accepted for Oral Presentation at the 2013 Society of Surgical Oncology (SSO) Annual Meeting, National Harbor, MD. e-Pub 2013.
Torres KE, Vu T, Liu J, Lusby K, Kivlin C, Demicco E, Zhou F, Young E, Ingram D, Belousov R, Ma XY, Lazar A, Lev D. Role of AXL as Potential Therapeutic Target for Pleomorphic and Dedifferentiated Liposarcomas. Accepted for poster presentation at the 2012 Connective Tissue Oncology Society (CTOS) Annual Meeting, Prague, Czech Republic. e-Pub 2012.
May C, Vu T, Liu J, Zhou F, Ma X, Ingram D, Belousov R, Han L, Lazar J, Lev D, Torres KE. Role of AXL as a Potential Therapeutic Target for Pleomorphic and Dedifferentiated Liposarcoma. Accepted for poster presentation at the Cancer Biology Chair and Director's Retreat, La Jolla, CA. e-Pub 2012.
Torres KE, Kin K, Yi M, Lahat G, Arun B, Hunt KK, Pollock R, Lev D. Analysis of Radiation-Associated Angiosarcoma of the Breast. Accepted for oral presentation at the 2022 Society of Surgical Oncology (SSO) Annual Meeting, Orlando, FL. e-Pub 2012.
Lopez G, Ghadimi M, Liu L, Belousov R, Torres KE. Drug-Induced Authophagy as a Mechanism of Therapeutic Resistance in MPNST. Accepted for poster presentation at the 2021 Connective Tissue Oncology Society (CTOS) Annual Meeting, Chicago, IL. e-Pub 2011.
Demicco E, Torres KE, Ghadimi M, Colombo C, Bolshakov S, Peng T, Hoffman A, Bovee J, Wang WL, Lev D, Lazar A. Involvement of the PI3K/AKT Pathway in Myxoid & Round Cell Liposarcoma. Accepted for poster presentation at the 2011 Connective Tissue Oncology Society (CTOS) Annual Meeting, Chicago, IL. e-Pub 2011.
Lusby K, Torres KE, Kivlin C, Liu J, Vu T, Young E, Lazar A, Lev D. Expression of ―Drugable‖ Tryosine Kinase Receptors in MPNST: A Potential Role for AXL as a Novel Therapeutic Target. Accepted for oral presentation at the 2011 Connective Tissue Oncology Society (CTOS) Annual Meeting, Chicago, IL. e-Pub 2011.
Torres KE, Kin K, Lahat G, Arun B, Hunt KK, Pollock R, Lev D. Radiation-Associated Angiosarcoma of the Breast: A Single Institution Experience. Accepted for poster presentation at the 2011 Connective Tissue Oncology Society (CTOS) Annual Meeting, Chicago, IL. e-Pub 2011.
Bill KL, Young E, Belousov R, Peng T, Nguyen T, Bolshakov S, Lazar A, Torres KE, Lev D. Met Signaling Contributes to Liposarcoma Growth, Migration, and Invasion: A Potential Molecular Therapeutic Target. Accepted for poster presentation at the 2011 Connective Tissue Oncology Society (CTOS) Annual Meeting, Chicago, IL. e-Pub 2011.
Torres KE, Bill K, Lahat G, Liu J, Ghadimi M, Belousov R, Young E, Lopez G, Lazar A, Lev D. Met Receptor: A Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors. Accepted for poster presentation at the 2011 Society of Surgical Oncology (SSO) Annual Meeting, San Antonio, TX. e-Pub 2011.
Lahat G, Tuvin D, Torres KE, Feig B, Cormier J, Hunt KK, Pisters P, Lev D, Pollock R. Extremity High Grade Soft Tissue Sarcoma (STS): Outcomes in Patients with Primarily Negative vs Positive Converted to Negative Microscopic Margins Following Re-excision. Accepted for oral presentation at the 2010 Connective Tissue Oncology Society (CTOS) Annual Meeting, Paris, France. e-Pub 2010.
Ghadimi MP, Ghadimi MP, Liu P, Liu P, Peng T, Peng T, Torres KE, Torres KE, Young E, Young E, Wang W, Wang W, Broccoli D, Broccoli D, Lazar A, Lazar A, Pollock R, Pollock R, Lev D, Lev D. A Comprehensive Clinicopathological Study of Pleomorphic Liposarcomas. Accepted for poster presentation at the 2010 Connective Tissue Oncology Society (CTOS) Annual Meeting, Paris, France. e-Pub 2010.
Lahat G, Zhu Q, Huang F, Bolshakov S, Liu J, Torres KE, Robert L, Lazar AL, Hung M, Lev D. Withaferin-A Inhibits the Growth, Local Recurrence, and Metastasis of Genetically Complex STS. Accepted for poster presentation at the 2010 Connective Tissue Oncology Society (CTOS) Annual Meeting, Paris, France. e-Pub 2010.
Torres KE, Ghadimi M, Bill K, Liu J, Wang S, Lazar A, Pollock RE, Lev D. Role of C-MET As a Prognostic Factor and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors. Accepted for oral presentation at the 2010 Connective Tissue Oncology Society (CTOS) Annual Meeting, Paris, France. e-Pub 2010.
Lopez G, Torres KE, Hernandez B, Liu J, Young E, Belousov R, Bolshakov S, Nguyen T, McConkey D, Lev D. Neurofibromatosis Type-1 Associated MPNST Are Highly Sensitive To Histone Deacetylase Inhibitors. Accepted for oral presentation at the 2010 Connective Tissue Oncology Society (CTOS) Annual Meeting, Paris, France. e-Pub 2010.
Torres KE, Lopez G, Liu J, Pollock RE, Lev DC. 87. Role of Drug-Induced Autophagy in Malignant Peripheral Nerve Sheath Tumors (MPNST); A Mechanism of Drug Resistance. Accepted for poster presentation at the 2010 American Association for Cancer Research (AACR) Annual Meeting, Washington, DC. e-Pub 2010.
Lopez G, Liu J, Torres KE, Pollock RE, Lev DC. Histone Deacetylase Inhibitor (HDACi)-Induced Autophagy in Malignant Peripheral Nerve Sheath Tumors (MPNST); A Mechanism of Drug Resistance. Accepted for abstract presentation at Keystone Symposia: Cell Death Pathways: Apoptosis, Autophagy and Necrosis, Vancouver, Canada. e-Pub 2010.
Wang S, Ren W, Liu J, Lahat G, Torres KE, Lopez G, Lazar AJ, Hayes-Jordan A, Liu J, Bankson KJ, Hazle JD, Lev D. TRAIL and Doxorubicin Combination Induces Pro-Apoptotic and Anti-Angiogenic Effects in Soft Tissue Sarcoma in Vivo. Accepted for poster presentation at the 2009 Connective Tissue Oncology Society (CTOS) Annual Meeting, Miami, FL. e-Pub 2009.
Montgomery AE, Shanneik Y, Ma E, Mardick JI, Wolfe CA, Bench S, Munnangi P, Gingrich A, Landers S, Wangsiricharoen S, Bhalla A, Lin PP, Lewis VO, Moon BS, Patel SS, Lyu H, Lillemoe H, Scally C, Keung E, Roland CL, Hunt KK, McCutcheon I, Bird JE, Yu W, Torres KE, Eberlin LS. Evaluation of the MasSpec Pen Technology for Molecular Identification of Soft-Tissue Sarcomas and Surgical Margin Assessment. Accepted for poster presentation at the ASMS Conference on Mass Spectrometry and Allied Topics. San Diego, CA.
Raj R, Vilson R, Joseph C, Lin HY, Munnangi P, Nakazawa MS, Torres KE, Araujo DM, Benjamin RS, Conley AP, J Livingston JA, Ludwig JA, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Somaiah N. NF1- and Non-NF1–Associated Malignant Peripheral Nerve Sheath Tumors (MPNST): The University of Texas MD Anderson (MDACC) Experience. Poster presentation at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting, Chicago, IL.
Elmorsi R, Camacho L, Krijgh DD, Lyu H, Roubaud MS, Torres KE, Lewis VO, Roland CL, Mericli AF. Anderson Sarcoma Reconstruction Outcomes CALculator (SaRCal): A Validated, Radiomics-based, Machine Learning-Powered Tool. American Association of Plastic Surgeons (AAPS) Annual Meeting, Austin, TX.
Wong J, Bhalla, A, Gu Y, Daphne H, Landers SM, Scheet P*, Torres KE*. High- and Modest-depth Whole Genome Sequencing to Identify MPNST using Blood-based Biomarkers. 2025 American Society of Human Genetics (ASHG) Annual Meeting, Boston, MA.
Raj R, Munnangi P, Yi M, Joseph C, Thirasastr P, Landers SM, Woodruff G, Bhalla AD, Somaiah N, Nassif Haddad EF, Valenzuela RF, Roland CL, Scally CP, Keung EZ, Lyu HG, Lillemoe HA, McCutcheon I, Slopis JM, Hunt KK, Torres KE. The Role of Socioeconomic disparities on Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors. Accepted for Poster presentation at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting, Boca Raton, FL.
Lyu HG, Roy P, Pan C, Prakash L, Wang L, Torres KE, Kelly K Hunt KK, Lillemoe HA, Scally CP, Katz MHG, Keung EZ, Roland CL. Leveraging Large Language Models to Extract Sarcoma-specific Data and Outcomes from Clinical Notes. Accepted for oral presentation at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting, Boca Raton, FL.
Nassif Haddad EF, Osman NM, Shamsutdinova D, Wani KM, Ingram DR, Arunkumar V, Ratan R, Torres KE, Nakazawa MS, Farooqi A, Somaiah N, Patel S, Roland CL, MD, Lazar AJ, Keung EZ. Immune Profiling of Undifferentiated Pleomorphic Sarcomas Reveals Distinct Prognostic Subgroups. Accepted for Poster presentation at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting, Boca Raton, FL.
Thirasastr P, Raj R, Vilson RS, Joseph C, Lin H, Munnangi P, Torres KE, Araujo DM, Nassif Haddad EF, Zarzour MA, Iyer AV, Pemmanda M, Nakazawa MS, Ludwig JA, Benjamin RS, Conley AP, Livingston A, Patel S, Ratan R, Ravi V, Somaiah N. Outcomes of Later-Lines Systemic Therapies in Malignant Peripheral Nerve Sheath Tumors (MPNST). Accepted for Poster presentation at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting, Boca Raton, FL.
Denu RA, Singh A, Jiang Y, Zheng Z, Ingram DR, Wani KM, Kochat V, Landers SM, Bhalla AD, Padron W, Cai Y, Ying H, Lin H, Huse J, Keung EZ, Wang WL, Farooqi A, Conley AP, Patel S, Somaiah N, Lazar AJ, Nassif Haddad EF, Torres KE, Rai K. Prognostic and Biologic Significance of Atrx Mutation in Adult Soft Tissue Sarcoma. Accepted for oral presentation at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting, Boca Raton, FL.
Vavolizza R, Perez AN, Wingate E, Subramaniam A, Yi M, Keung EZ, Roland C, Torres KE, Scally CP, Lyu HG, Mitra D, Farooqi AS, Bishop AJ, Guadagnolo A, Yoder AK, Lazar A, Hunt KK, Ravi V, Lillemoe H. P8. Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes. Accepted for Poster presentation at the 2026 Society of Surgical Oncology (SSO) Annual Meeting, Phoenix, AZ.
Landry JP, Bhalla AD, Landers SM, Lazcano R, Parker LA, Miller TM, Niemi N, Lyu H, Lillimoe H, Keung EZ, Scally CP, Roland CL, Hunt KK, Slopis JM, McCutcheon IE, Boudreau B, Wilson-Robles H, Lazar AJ, Rai K, Wiener DJ, Davis BW, Wustefeld-Janssens B, Torres KE. Comparative Study of Human and Canine Nerve Sheath Tumors in Terms of Morphology, Prognosis, Treatment, Epigenetics, Transcriptomics, and Genomics. Accepted for Poster presentation at the 2026 American Association for Cancer Research (AACR), San Diego, CA.
Thirasastr P, Raj R, Vilson R, Joseph C, Iyer AV, Pemmanda M, Nakazawa MS, Torres KE, Araujo DM, Benjamin RS, Conley AP, J Livingston JA, Ludwig JA, Patel S, B Guadagnolo A, Vinod Ravi V, Zarzour MA, Nassif Haddad EF, Somaiah N. Role of Chemotherapy (CMT) in Localized High-Risk Malignant Peripheral Nerve Sheath Tumors (MPNST) Submitted. 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
Roland CL, Keung EZ, Lazar AJ, Torres KE, Wang WL, Guadagnolo A, Bishop AJ, Lin HY, Hunt K, Feig BW, Bird JE, Lewis VO, Tawbi AH, Ratan R, Patel S, Wargo JA, Somaiah N. Preliminary Results of a Phase II Study of Neoadjuvant Checkpoint Blockade for Surgically Resectable Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS). Accepted for poster presentation at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

Book Chapters

Torres KE, McCutcheon I. Neurogenic Tumors (Schwannoma, Neurofibroma, and MPNST) for Complex General Surgical Oncology. In: Official publication of the Society of Surgical Oncology (SSO). Decker Intellectual Properties Inc, Canada, 2018.
Keung EZ, Pollock RE, Hunt KK, Torres KE. Forequarter Amputation. In: Master Techniques in Surgery: Breast Surgery. Walters Kluwer, Lippincott Williams & Wilkins. Philadelphia, PA, 2018.
Torres KE, Pisters PW. Malignant Fibrous Histiocytoma. In: Sarcoma Oncology: A Multidisciplinary Approach. People's Medical Publishing House-USA, Ltd, China, 2014.
Brewer K, Torres KE, Lev D. Tumor Microenvironment Cross-Talk; a Process Critical for Sarcoma Progression and Metastasis. In: Sarcoma Oncology: A Multidisciplinary Approach. People's Medical Publishing House - USA, Ltd. China, 2014.
Torres KE, Pollock RE. Soft Tissue Sarcomas. In: New EBM Textbook of Elective General Surgery. People's Medical Publishing House - USA, Ltd. China, 2012.
Torres KE, Hunt KK, Pollock RE. Forequarter Amputation. In: Master Techniques in Breast Surgery. Lippincott Williams & Wilkins, New York, NY, 2010.
Torres KE, Pollock RE. Gene-Based Therapies for Cancer. In: Cancer Research. Springer, New York, 2010.
Torres MB, Gingrich AA, Torres KE. Surgical Treatment of Dermatofibrosarcoma Protuberans and Cutaneous Leiomyosarcoma. In: Difficult Decisions in Surgery: An Evidence-Based Approach. In: Difficult Decisions in Surgical Oncology. Ed. Ben Ferguson, Michael G. White and Puneet Singh. Springer Nature, Chenna, India. In Press.

Patents

Submitted invention disclosure report, Alexander Lazar, M.D., Ph.D., Keila Enitt Torres, M.D., Ph.D. MBA, and Neeta Somaiah, M.D., Establishing and characterizing liposarcoma cell lines, United States, MDA21-071, Current IDR status: Commercialize.
Submitted invention disclosure report, Keila Enitt Torres, M.D., Ph.D., MBA and Alexander Lazar, M.D., Ph.D., Pre-clinical models of malignant peripheral nerve sheath tumor (MPNST) and undifferentiated pleomorphic sarcoma (UPS), United States, MDA21- 03756, Current IDR status: Commercialize.

Less

CV information above last modified March 25, 2026

Keila E. Torres, MD, PhD, MBA, FACS

About Dr. Keila E. Torres

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Professional Educational Materials

Other Articles

Abstracts

Book Chapters

Patents

Patient Reviews

Related Links

Torres Laboratory

Surgical Oncology department

Surgery division

Help #EndCancer

Keila E. Torres, MD, PhD, MBA, FACS

About Dr. Keila E. Torres

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Professional Educational Materials

Other Articles

Abstracts

Book Chapters

Patents

Patient Reviews

Request an Appointment

Related Links

Torres Laboratory

Surgical Oncology department

Surgery division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson